

Organized by



MMOF

1st Congress of the
**Mediterranean
Multidisciplinary
Oncology
Forum**

10 - 13 September 2009

Astir Palace Resort
Athens, Greece

www.MediterraneanOncologyForum2009Athens.gr



Accredited with 24 ESMO-MORA points
Category 1

Blocks EGFR – opens new options

**ERBITUX® - Στη 1η γραμμή θεραπείας
της μεταστατικής νόσου του παχέος εντέρου^{1,2,3}**



ONC/40/07.08

Merck Serono Oncology | Combination is key™

Ονομασία του φαρμακευτικού προϊόντος: Erbitux® 5 mg/ml διόλυμπο για έγχυση. **Ποιοτική και ποσοτική σύνθεση:** κάθε ml του διολύματος για έγχυση περιέχει 5 mg cetuximab. Κάθε φιαλίδιο περιέχει 10 ml, 20 ml, 50 ml ή 100 ml. Το cetuximab είναι ένα χιμικό μονοκανθικό αντιόιδιο IgG1 παρούρανος σε γραμμή κυτταρών θηλωτικών ανασυνδυσμένου DNA. **Αντενέδειξη:** Το Erbitux® αντενέδειξεται σε ασθενείς σα οδφαρές [βαθμός 3 & 4] αντιδράσεις υπερευαισθησίας στο cetuximab. Πριν την έναρξη της θεραπείας αναδύομενο, πρέπει να εξετάζονται οι αντενέδειξης για τους παραπλόλη ρυγχομονωμένους χημειοθεραπευτικών παράργαντος ή την ακτινοθεραπεία. Ειδικές προειδοποίησης και προφύλαξης κατά τη χρήση. **Αντιδράσεις ασκετίζομενες με την έγχυση:** Έχουν αναφερεί οσβαρές αντιδράσεις ασκετίζομενες με την έγχυση σε ασθενείς που υποβλήθηκαν σε θεραπεία με cetuximab. Το αυμπτώματο συνήθως παρουσιάστηκαν κατά τη διάρκεια της πρώτης έγχυσης και μέχρι 1 ώρα μετά το τέλος της έγχυσης, μπορούν όμως να παρουσιάσουν και μετά από ορεκτές ώρες ή και με τελετέστη εγκύων Η εφαρμοσία ασθράφτη αντιδράσεως ασκετίζομενης με την έγχυση επιβλέπει την άμεση και μόνιμη διακοπή της θεραπείας με cetuximab και μπορεί να αποτελεί αντιεπιτόπιο επίκτητος ανάγκης. Συνιστάται ειδική προσοχή για ασθενείς που κατόπιν μεμενώνες απόδοσης και προηγούμαντα καρδιοπάθεμα νόσου. Διαταραχές του αναπνευστικού συστήματος: Εχουν αναφερεί μεμονωμένες περιπτώσεις διάμεσους πνευμονικών διστοραγών όγκων οι οποίες σχέτεση με το cetuximab. Σε περίπτωση διάγνωσης διάμεσης πνευμονικής νόσου, το cetuximab πρέπει να διακοπεί και ο οδφαρής να υποβληθεί στην κατόλληλη θεραπεία. **Δερματικές αντιδράσεις:** Εάν ένας ασθενής εφαρμόνισε σοδφαρή δερματική αντιδράση, η θεραπεία με cetuximab πρέπει να διακοπεί. Η θεραπεία μπορεί να αρχίσει εκ νέου μόνο εάν η αντιδράση έχει υπωχορήσει σε αντιδράση βαθμού 2. Εάν η σοδφαρή δερματική αντιδράση παρουσιάστηκε για πρώτη φορά, η θεραπεία μπορεί να αρχίσει εκ νέου καρίς αλλού στην επόμενη δόση. Σε περίπτωση που οι σα οδφαρές δερματικές αντιδράσεις παρουσιάστηκαν για δεύτερη και τρίτη φορά, η θεραπεία με cetuximab πρέπει και πάλι να διακοπεί. Η θεραπεία μπορεί να αρχίσει εκ νέου μόνο σε χαμηλότερη επίδειξη δόσης [200 mg/m² συμβατικές επιφάνειας μετά τη δεύτερη εφαρμόσιον και 150 mg/m² μετά την τρίτη εφαρμόσια], εάν η αντιδράση έχει υπωχορήσει σε αντιδράση βαθμού 2. Εάν οι οδφαρές δερματικές αντιδράσεις εμφανιστούν μία τέταρτη φορά ή δεν υπωχορήσουν σε αντιδράσεις βαθμού 2 κατά τη διάρκεια της διακοπής της θεραπείας, αποτελεί μόνιμη διακοπή της θεραπείας με cetuximab. **Διαταραχές των ηλεκτρολυτών:** Παρουσιάζεται συχνά σοδφαρή υπογονηστισμοί. Η υπογονηστισμοί είναι ανοστρέψιμη μετά από τη διακοπή του cetuximab. Επιπλέον, πολαιολύμπια μπορεί να αναπτυχθεί μετά από τη διακοπή του cetuximab. Διαταραχές της θεραπείας με cetuximab καθώς και περιοδικά κατά τη διάρκεια ασθενείας. Συνιστάται αναπλήρωση των πλεκτρόλυτων, αύμηνα που με τις ανάγκες. **Ουδετεροπανία και ασκετίζομενες επιπλοκές:** Ασθενείς που λαμβάνουν cetuximab σε ανυδριασμό με χημειοθεραπεία με βάση την πλατινίνα διατρέχουν αυξημένο κίνδυνο να εμφανίσουν σοδφαρή ουδετεροπανία, ο οποίο μπορεί να οδηγήσει σε επακόλουθες λοιμώδεις επιπλοκές όπως εγκύρωτη ουδετεροπανία, πνευμονία ή σπλην. Συνιστάται προσεκτική ποροκαλούθηση για τους ουσικούς ασθενείς, ειδικά εκείνους που παρουσιάζουν δερματικές ή βλεννογόνιτιδα διάρροια, που μπορεί να διευκολύνει την εφαρμόσιμη λοιμώδεις Κόπη και γαλονιάς: Συνιστάται ιδιαιτέρω η κορήγηση του Erbitux® κατά την κύπον ή σε οποιαδήποτε γνάνεια δεν χρησιμοποιεί επαρκή αντιστολή για να γίνεται μόνο εάν το ενδικούμενο θεραπευτικό άρθρο δικαιολογεί τον πιθανό κίνδυνο για το νεογάν. Δεν συνιστάται η θλιπάση σε πάντα τη διάρκεια της θεραπείας με Erbitux® και για 2 μήνες μετά την τελετουργία δόσης. **Ανεπιθύμητες ενέργειες:** Πολύ συχνές [≥ 1/10]: δερματικές αντιδράσεις, υπομονοποιημός, πέπτις ή μέτριες αντιδράσεις σχετίζομενες με την έγχυση, πόνος ή έμετρο βλεννογόνιτο, ούποντα πιποτικών ενδύμαν. Συχνές [≤ 1/100, < 1/10]: κεφαλολύμπια, επιπεγκάπτιδα, διάρροια, νυσταΐα, έμετρο, κατοβράζια, αφαύτηση, απώλεια βάρους, βαριές αντιδράσεις ασκετίζομενες με την έγχυση. Οιχι συχνές [≤ 1/1,000, < 1/100]: βλεφαρίτις, κερατίτις, εν τω βάθει φλεβική θρόμβωση, πνευμονική ευβούλη. Συχνότητα δεν είναι γνωστή: ερυθητισμός, σύνδρομος τοξικής επιδερμικής νεκρώσεως [όπως βλεννογόνιτο δερματοβιβλια, θυραφάρη ή λευκονευρία, κυρίως εκφραστέων με λευκοφυτοπανεργία], θεραπεία ανυδριασμό: Όταν το cetuximab χρησιμοποιείται σε ανυδριασμό με χημειοθεραπευτικούς παράγοντες, αντέτεις επίσης στις αντίστοιχες πληροφορίες προϊόντος. Σε ανυδριασμό με χημειοθεραπεία με βάση την πλατινίνα, ο συχνότητα σοδφαρής λευκοπενίας ή σοδφαρής ουδετεροπανίας μπορεί να είναι αυξημένη, οδηγώντας σε αυξημένη λοιμώδεις επιπλοκές που συμπεριλαμβανούνται του εφραγμάτου του μυοκαρδίου και της συμφορτικής κορδιακής ονειράσεις, καθώς και η συχνότητα του συνδρόμου ωριμό-ποδιών αυθιζητών. Σε ανυδριασμό με την τοπική ακτινοθεραπεία, η συχνότητα της καρδιοκαταρράκτης ή των τραχηλών, επιπλοβάσεως ανεπιθύμητες ενέργειες πάντα της ακτινοθεραπείας. Περισσότερες πληροφορίες περιλαμβάνονται στην περιήγηση καρκινοτριπτικών του προϊόντος, το φιλόλ οδηγώντας και τη μονογραφία του φορμάκου. Λιανική Τιμή: 322,26€

Βιβλιογραφία

1. ERBITUX® Summary of Product Characteristics
 2. Van Cutsem et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. *N Engl J Med* 2009; 360:1408-17.
 3. Bokemeyer et al. FOLFOX with or without Cetuximab in the first-line Treatment of Metastatic Colorectal Cancer. *J Clin Oncol* 2008 20 8397

Βοηθείστε να γίνουν το μόνιμο

πιο οσπολή·

πο ασφαλή.

"K

- ΟΛΕΣ τις ανεπιθύμητες ενέργειες για τα Νέα φάρμακα **Ν**
 - Τις ΣΟΒΑΡΕΣ ανεπιθύμητες ενέργειες για τα Γνωστά φάρμακα

Merck A E Hellas

Merck A.E. Hellas
Δ. Κηφισίας 41-45 (Κτίο Β)

Α. Κηφισίας 41-4
151 23 Μονούσι

Tηλ: +30 210 6165100

ΦΩΣ: +30 210 6103378

MERCK SERONO

Under the auspices of:



Ministry of Health
and Social Solidarity



European Society
of Surgical Oncology (ESSO)



1985



Turkish Oncology Society

With the participation of:



Mastology Association
of Northern and Southern Mediterranean (MANOSMED)

contents

Welcome Letter.....	3
Committees.....	4-7
Faculty	8-10
Scientific Programme.....	11-29
General Information.....	32-35
Acknowledgments	37
Exhibition Plan.....	38
Congress Proceedings.....	39-160
● Invited Abstracts.....	41-95
● Proffered Papers (O1-O30).....	97-112
● Poster Presentations (P1-P49).....	113-138
● Publications (01-46).....	139-160
Authors' Index.....	161-168





Vectibix® (panitumumab)

VECTIBIX® 20mg/ml πυκνό διάλυμα για παρασκευή διαλύματος προς έγχυση.
Κάθε φιαλίδιο περιέχει
100mg Panitumumab σε 5 ml.
ΓΙΑ ΠΕΡΙΣΣΟΤΕΡΕΣ ΠΛΗΡΟΦΟΡΙΕΣ
ΕΠΙΚΟΙΝΩΝΗΣΤΕ ΜΕ ΤΗΝ
AMGEN ΕΛΛΑΣ Ε.Π.Ε.

AMGEN®

Amgen Ελλάς Ε.Π.Ε.
Γραβιάς 4
151 25, Μαρούσι
Τηλ.: 210 344 7000
Fax: 210 344 7050

AH/BUO/VEC/04-2008/007



Dear Colleagues, Dear Friends,

It is a great honour and pleasure for me, to welcome you, on behalf of the Board of Directors of MMOF, to the 1st Congress of the Mediterranean Multidisciplinary Oncology Forum, held in the beautiful city of Athens, 10-13 September 2009, at the Astir Palace Resort of Athens.

The success of the Hellenic -Turkish ESMO Advanced Courses, held in Istanbul and Athens in 2006 and 2007, lead us to the constitution of a major Oncology Forum with the participation of all Mediterranean countries. We hope to give the opportunity to different schools of Oncology, different civilizations and mentalities to share their knowledge and experience in Oncology.

The historical city of Athens, the birthplace of Socrates and Plato, the home of philosophy, democracy and culture is an ideal setting for such an important event and a promising start for something new.

We are pleased to prepare and present a comprehensive scientific program with "state of the art" lectures by world-renowned scientists, plenary symposia, proffered papers and special workshops for Mediterranean young Oncologists.

In addition the "2nd BREAST CANCER DAY", a special satellite scientific event, sponsored by ROCHE, in which distinguished speakers from across the globe will provide their expert perspectives on BREAST Cancer, will take place on Friday morning, 11th of September 2009.

Wishing and hoping to share with all of you a creative and productive scientific event in Greece, we welcome you in Athens for the 1st MMOF Congress.

Dr. Dimitrios I. Bafaloukos

A handwritten signature in black ink, appearing to read "D. Bafaloukos".

President of MMOF
Chairman of the Congress



committees

Organising Committee (Board of Directors of MMOF)

Honorary President:

Paris Kosmidis, Medical Oncologist, Greece

Chairman / President:

Dimitrios Bafaloukos, Medical Oncologist, Greece

Vice President:

Haluk Onat, Medical Oncologist, Turkey

General Secretary- Membership Committee Chair:

Gokhan Demir, Medical Oncologist, Turkey

General Secretary- Educational Committee Chair:

Helena Linardou, Medical Oncologist, Greece

Multidisciplinary Oncology Committee Chair:

George Asimakopoulos, Breast Surgeon, Greece

Treasurer:

Ourania Nicolatou-Galitis, Dentist-Oral Oncology, Greece

Meditteranean Executive Officer:

Alessandro Testori, Medical Oncologist, Italy

Members:

Pinar Saip, Medical Oncologist, Turkey

Idris Yücel, Medical Oncologist, Turkey

Local Organising Committee

Chairman:

Papadimitriou Christos, Medical Oncologist, Greece

Members:

Agelaki Sofia, Medical Oncologist, Greece

Andreadis Charalambos, Medical Oncologist, Greece

Aravantinos Gerasimos, Medical Oncologist, Greece

Beroukas Ernestos, Radiation Oncologist, Greece

Christopoulou Athina, Medical Oncologist, Greece

Kalofonos Charalambos, Medical Oncologist, Greece

Kanaloupti Dimitra, Internist, Greece

Karageorgis Pantelis, Radiation Oncologist, Greece

Kolokotronis Alexandros, Dentist-Oral Oncology, Greece

Mountzios Ioannis, Medical Oncologist, Greece

Pantelakos Panagiotis, Radiation Oncologist, Greece

Petraki Kalliopi, Pathologist, Greece

Rologis Dimitrios, Neurosurgeon, Greece

Samantas Epaminondas, Medical Oncologist, Greece

Tarampikou Anthi, Oncology Nurse, Greece

Tsakiris George, Radiation Oncologist, Greece

Tsiotos Grigorios, Surgeon, Greece

Zervoudis Stefanos, Breast Surgeon, Greece



Scientific Committee**Chairpersons:**

Linardou Helena, Medical Oncologist, Greece

Demir Gokhan, Medical Oncologist, Turkey

Members:

Bamias Aristotle, Medical Oncologist, Greece

Bavbek Sevil, Medical Oncologist, Turkey

Briasoulis Evangelos, Medical Oncologist, Greece

Christodoulou Christos, Medical Oncologist, Greece

Elad Sharon, Dentist-Oral Oncology, Israel

Gaafar Rabab, Medical Oncologist, Egypt

Garassino Marina, Medical Oncologist, Italy

Gökmen Erhan, Medical Oncologist, Turkey

Jezdic Svetlana, Medical Oncologist, ESMO Head Office

Karagianni Aikaterini, Dentist-Oral Oncology, Greece

Karamouzis Mihalis, Medical Oncologist, Greece

Kardamakis Dimitrios, Radiation Oncologist, Greece

Kav Sultan, Oncology Nurse, Turkey

Klein Baruch, Medical Oncologist, Israel

Koutras Aggelos, Medical Oncologist, Greece

Mayordomo Jose Ignacio, Medical Oncologist, Spain

Metaraku Donika, Medical Oncologist, Malta

Molinias Mandel Nil, Medical Oncologist, Turkey

Murray Samuel, Molecular Biologist, Greece

Ober Ahmet, Radiation Oncologist, Turkey

Palla Katerina, Haematologist, Greece

Papakostas Pavlos, Medical Oncologist, Greece

Papamichael Dimitris, Medical Oncologist, Cyprus

Patiraki Elisavet, Oncology Nurse, Greece

Pleština Stjepko, Medical Oncologist, Croatia

Poulakaki Fiorita, Breast Surgeon, Greece

Retsas Spyros, Medical Oncologist, UK

Rosti Giovanni, Medical Oncologist, Italy

Saip Pnar, Medical Oncologist, Turkey

Skarlos Dimosthenis, Medical Oncologist, Greece

Yarden Yosef, Molecular Biologist, Israel

Abstract Review Committee

Linardou Helena, Medical Oncologist, Greece

Andreadis Charalambos, Medical Oncologist, Greece

Boukovinas John, Medical Oncologist, Greece

Droufakou Stravroula, Medical Oncologist, Greece

Koutras Aggelos, Medical Oncologist, Greece

Murray Samuel, Molecular Biologist, Greece

Proffered Papers Award Committee

Demir Gokhan, Medical Oncologist, Turkey

Dubois Jean-Bernard, Medical Oncologist, France

Economopoulos Theophanis, Medical Oncologist, Greece

Pavlidis Nikos, Medical Oncologist, Greece

Rosti Giovanni, Medical Oncologist, Italy

Poster Award Committee

Christodoulou Christos, Medical Oncologist, Greece

Navrozoglou Iordanis, Gynaecologist, Greece

Zervoudis Stefanos, Breast Surgeon, Greece

International Advisory Committee, National Representatives

Chairman

	Greece	Penthaloudakis George, Medical Oncologist
---	--------	---

Members

	Albania	Sallaku Agim, Medical Oncologist
	Algeria	Boubrit Mustapha, Oncology Surgeon
	Bosnia and Herzegovina	Beslija Semir, Medical Oncologist
	Croatia	Pleština Stjepko, Medical Oncologist
	Cyprus	Adamou Adamos, Medical Oncologist
	Egypt	Gaafar Rabab, Medical Oncologist
	France	Lamarque Jean-Louis, Oncology Surgeon
	Greece	Samonis George, Medical Oncologist
	Israel	Sulkes Aaron, Medical Oncologist
	Italy	Testori Alessandro, Medical Oncologist
	Lebanon	Geahchan Negib, Oncology Surgeon
	Libya	El Mistiri Mufid, Medical Oncologist
	Malta	Metaraku Donika, Medical Oncologist
	Monaco	Mourou Michel Yves, Oncology Surgeon
	Montenegro	Todorovic Vladimir, Medical Oncologist
	Morocco	Chafik Chraibi, Oncology Gynaecologist
	Spain	Tabernero Josep, Medical Oncologist
	Slovenia	Matos Erika, Medical Oncologist
	Syria	Jadid Hasan, Oncology Surgeon
	Tunisia	Radhi Hamza, Medical Oncologist
	Turkey	Suayib Yalcin, Medical Oncologist



faculty

Adamou Adamos	Medical Oncologist, Cyprus
Androulakis George	Surgeon, Greece
Aravantinos Gerasimos	Medical Oncologist, Greece
Arber Nadir	Medical Oncologist, Israel
Asimakopoulos Georgios	Breast Surgeon, Greece
Askoxilakis Ioannis	Breast Surgeon, Greece
Atay Sevcan	Oncology Nurse, Turkey
Athanasiades Helias	Medical Oncologist, Greece
Aysin Kayis	Oncology Nurse, Turkey
Bafaloukos Dimitrios	Medical Oncologist, Greece
Balaska Georgia	Psychologist, Greece
Bamias Aristotle	Medical Oncologist, Greece
Bavbek Sevil	Medical Oncologist, Turkey
Beqiri Arben	Oncology Surgeon, Albania
Berkarda Bulent	Medical Oncologist, Turkey
Besse Benzamin	Medical Oncologist, France
Boleti Ekaterini	Medical Oncologist, UK
Bouzid Tarek	Medical Oncologist, Tunisia
Briasoulis Evangelos	Medical Oncologist, Greece
Casali Paolo G.	Medical Oncologist, Italy
Chabannon Christian	Cell Biologist, France
Charalambous Andreas	Oncology Nurse, Cyprus
Chraibi Chafik	Gynaecologist, Maroco
Christodoulou Christos	Medical Oncologist, Greece
Christopoulou Athena	Medical Oncologist, Greece
Crino Lucio	Medical Oncologist, Italy
Demir Gokhan	Medical Oncologist, Turkey
Demirkazik Ahmet	Medical Oncologist, Turkey
Douzinis Makis	Thoracic Surgeon, Greece
Di Nicolantonio Federica	Molecular Biologist, Italy
Dubois Jean-Bernard	Radiation Oncologist, France
Efremidis Anna	Medical Oncologist, Greece
Elad Sharon	Dentist-Oral Oncology, Israel
Ellis Paul	Medical Oncologist, UK
Emmanouilides Christos	Medical Oncologist, Greece
Fernandez-Ortega Paz	Oncology Nurse, Spain
Ficarra Vincenzo	Urologist, Italy
Franceschi Silvia	Medical Oncologist, France
Fumoleau Pierre	Medical Oncologist, France
Gaafar Rabab	Medical Oncologist, Egypt
Garassino Marina	Medical Oncologist, Italy
Georgiadis Konstantinos	Technician-Radiologist, Greece
Gogas Helen	Medical Oncologist, Greece
Gundogdu Fatma	Oncology Nurse, Turkey
Ignatiadis Michail	Medical Oncologist, Belgium




Ježdic Svetlana	Medical Oncologist, Switzerland
Kakolyris Stylianos	Medical Oncologist, Greece
Kalofonos Charalambos	Medical Oncologist, Greece
Karagianni Aikaterini	Dentist-Oral Oncology, Greece
Karamouzis Michalis	Medical Oncologist, Greece
Kardamakis Dimitrios	Radiation Oncologist, Greece
Karlou Chrysoula	Oncology Nurse, Greece
Katsaragakis Stylianos	Oncology Nurse, Greece
Kav Sultan	Oncology Nurse, Turkey
Kaynak Kamil	Thoracic Surgeon, Turkey
Klein Baruch	Medical Oncologist, Israel
Kosmidis Paris	Medical Oncologist, Greece
Kottaridis Panos	Haematologist, UK
Lemonidou Chrysoula	Oncology Nurse, Greece
Linardou Helena	Medical Oncologist, Greece
Loupakis Fotios	Medical Oncologist, Italy
Piulats Jose M.	Medical Oncologist, Spain
Maniadakis Nikos	Economist, Greece
Marinos Nikos	Radiation Oncologist, Greece
Mayordomo Jose Ignacio	Medical Oncologist, Spain
Michailidis Michail	Technician-Radiologist, Greece
Milani Alessandra	Oncology Nurse, Italy
Molinás Mandel Nil	Medical Oncologist, Turkey
Mountzios Ioannis	Medical Oncologist, Greece
Murray Samuel	Molecular Biologist, Greece
Navrozoglou Iordanis	Gynaecologist, Greece
Nicolatou Galitis Ourania	Dentist-Oral Oncology, Greece
Onat Haluk	Medical Oncologist, Turkey
Papadimitriou Christos	Medical Oncologist, Greece
Papadouri Anna	Oncology Nurse, Greece
Papageorgiou Dimitrios	Oncology Nurse, Greece
Papakostas Pavlos	Medical Oncologist, Greece
Papamichael Dimitrios	Medical Oncologist, Cyprus
Papandreou Christos	Medical Oncologist, Greece
Pappa Theodora	Oncology Nurse, Greece
Patiraki Elisavet	Oncology Nurse, Greece
Pectasides Dimitrios	Medical Oncologist, Greece
Penthaloudakis George	Medical Oncologist, Greece
Petridou Eleni	Epidemiologist, Greece
Peterson Douglas	Dentist-Oral Oncology, USA
Pleština Stjepko	Medical Oncologist, Croatia



faculty

Porta Camillo	Medical Oncologist, Italy
Poulakaki Fiorita	Breast Surgeon, Greece
Psirri Amanta	Medical Oncologist, Greece
Psychogiou Argyro	Oncology Nurse, Greece
Razis Evangelia	Medical Oncologist, Greece
Retsas Spyros	Medical Oncologist, UK
Rosti Giovanni	Medical Oncologist, Italy
Roussakis Sotirios	Oncology Nurse, Greece
Saip Pinar	Medical Oncologist, Turkey
Samantas Epameinondas	Medical Oncologist, Greece
Samonis George	Medical Oncologist, Greece
Shamaa Sameh	Medical Oncologist, Egypt
Skarlos Dimosthenis	Medical Oncologist, Greece
Sotiriou Christos	Medical Oncologist, Belgium
Syrigos Konstantinos	Medical Oncologist, Greece
Tarampikou Anthi	Oncology Nurse, Greece
Testori Alessandro	Medical Oncologist, Italy
Thanos Dimitrios	Molecular Biologist, Greece
Tortora Giampaolo	Medical Oncologist, Italy
Tountas Ioannis	Epidemiologist, Greece
Trichopoulou Antonia	Biopathologist, Nutritionist, Greece
Tsakiris Georgios	Radiation Oncologist, Greece
Tsekeris Pericles	Radiation Oncologist, Greece
Tsiftsis Dimitrios	Surgeon, Greece
Tsiotos Grigoris	Surgeon, Greece
Veronesi Paolo	Surgeon, Italy
Viale Giuseppe	Pathologist, Italy
Viteri Santiago	Medical Oncologist, Spain
Vlastos George	Breast Surgeon, Switzerland
Vogel Victor	Medical Oncologist, USA
Xepapadakis Grigoris	Breast Surgeon, Greece
Yaffe Aliza	Oncology Nurse, Israel
Yalcin Suayib	Medical Oncologist, Turkey
Yarden Yosef	Molecular Biologist, Israel
Yucel Idris	Medical Oncologist, Turkey
Zervoudis Stefanos	Breast Surgeon, Greece
Zielinski Christoph	Medical Oncologist, Austria
Zografos George	Breast Surgeon, Greece

SCIENTIFIC PROGRAMME





Pfizer HELLAS AE

A. Mavrogianni 243, N. Filoxidi 154 51

Tel. Entriaprovouhi Evrytaniou: 210 6785800



09.00-10.00	Registration
10.00-10.30	Welcome and introduction
10.30-12.30	Symposium: "Multidisciplinary Approaches in Genitourinary Cancer"
10.30 - 11.30	1. Prostate Cancer Chairpersons: Ch. Papadimitriou (Greece), M.N. Molinas (Turkey) <ul style="list-style-type: none"> ● Novel approaches in the management of localized tumours: what and for whom? V. Ficarra (Italy) ● Hormone refractory prostate cancer: when to treat and how? J. M. Piulats (Spain) ● Novel targets and agents C. Papandreou (Greece)
11.30-12.30	2. Renal Cancer Chairpersons: S. Retsas (UK), Ch. Emmanouilides (Greece) <ul style="list-style-type: none"> ● Case 1: when is nephrectomy indicated? S. Bavbek (Turkey) ● Case 2: first line standard of care E. Boleti (UK) ● Treatment algorithm based on recent advances & Concluding remarks A. Bamias (Greece)
12.30-13.00	C o f f e e b r e a k
13.00-14.30	Proffered papers (Session I) "Translational Research" Chairpersons: E. Samantas (Greece) – C. Chraibi (Morocco) <ul style="list-style-type: none"> O 01. COMBINED TREATMENT WITH ANTIANGIOGENETIC AND ANTI-EGFR AGENTS IN GLIOBLASTOMA Giannopoulos E.¹, Dimitropoulos K.¹, Argyriou A.¹, Kalofonos Ch.¹ ¹Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, Greece O 02. THE RELATIONSHIP BETWEEN ANTIMETABOLITE TOXICITY AND PHARMACOGENETICS Dogan M.¹, Gurhan Karabulut H.², Tukun A.², Demirkazik A.¹, Ozal G.¹, Utkan G.¹, Yalcin B.¹, Dincel D.¹, Akbulut H.¹, Icli F.¹ ¹Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey, ²Ankara University School of Medicine, Department of Medical Genetics, Ankara, Turkey O 03. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR IN NON-SMALL CELL LUNG CANCER Yahia M.¹, Gaafar R.¹, Mansour O.¹, Elgamal B.², Aly Eldin N.³ ¹Department of Medical Oncology, National cancer Institute, Cairo University, Cairo, Egypt, ²Department of Clinical Pathology, National cancer Institute, Cairo University, Cairo, Egypt, ³Department of Epidemiology and Statistics, National cancer Institute, Cairo University, Cairo, Egypt O 04. THE EFFECT OF HER2 EXPRESSION ON CISPLATIN-BASED CHEMOTHERAPY IN ADVANCED NON- SMALL CELL LUNG CANCER PATIENTS Calikusu Z.¹, Yildirim Y.², Akcali Z.³, Sakalli H.³, Bal N.⁴, Unal I.⁵, Ozylkan O.³ ¹Department of Medical Oncology, Acibadem Hospital, Istanbul, Turkey, ²Department of Medical Oncology, Sivas Numune Hospital, Sivas, Turkey, ³Department of Medical Oncology, Baskent University Faculty of Medicine, Ankara, Turkey, ⁴Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey, ⁵Department of Biostatistics, Cukurova University Faculty of Medicine, Adana, Turkey O 05. INCREASED EXPRESSION OF NFY-C (NUCLEAR FACTOR Y, SUBUNIT C) AND RORA (RETINOIC ACID RECEPTOR- RELATED ORPHAN RECEPTOR ALPHA) IN COLORECTAL ADENOCARCINOMA. Kottarou A.¹, Antonacopoulou A.¹, Giannopoulou E.¹, Grivas P.¹, Scopa C.², Kalofonos Ch.¹ ¹Division of Oncology and Clinical Oncology Laboratory, Department of Internal Medicine, Medical School, University of Patras, Rio, Greece, ²Department of Pathology, Medical School, University of Patras, Rio, Greece



13.00-14.30

O 06.

WNT-1 EXPRESSION IS RELATED WITH LESS AGGRESSIVE PHENOTYPE IN PATIENTS WITH INVASIVE BREAST CARCINOMAS

Korakaki A.¹, Giannopoulou I.¹, Vamvakaris I.¹, Magkou C.¹, Theohari I.¹, Papadimitriou C.¹, Keramopoulos A.¹, Dimopoulos A.¹, Nakopoulou L.¹

¹1st Department of Pathology and Department of Clinical Therapeutic, Medical School, University of Athens, Greece

O 07.

IDENTIFICATION OF PATIENTS WHO MAY BENEFIT FROM THE PROPHYLACTIC CRANIAL RADIOTHERAPY AMONG BREAST CANCER PATIENTS WITH BRAIN METASTASIS.

Saip P¹, Cicin I.¹, Eralp Y.¹, Karagol H.¹, Kucucuk S.¹, Cosar Alas R.¹, Yavuz E.¹, Dincer M.¹, Saglam E.¹, Topuz E.¹

¹Department of Medical Oncology, Institute of Oncology, Istanbul University, Turkey.

O 08.

INTRAVENOUS (IV) IRON SUPPLEMENTATION IN CONJUNCTION WITH ERYTHROPOEISIS STIMULATING AGENTS (ESAS) IN CHEMOTHERAPY-INDUCED ANEMIA: META-ANALYSIS OF DATA FROM RANDOMIZED TRIALS

Rosti G.¹, Secondino S.², Giordano L.², Garassino I.², Gandini C.², Santoro A.², Pedrazzoli P.²

¹Medical Oncology Treviso, Italy, ²Humanitas Institute Rozzano, Italy

O 09.

H SOMATIC MUTATIONS IN KRAS: MECHANISM OF RESISTANCE TO ANTI-EGFR THERAPIES. SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES IN METASTATIC COLORECTAL CANCER

Kanaloupiti D.¹, Linardou H.¹, Dahabreh I.J.², Siannis F.³, Bafaloukos D.¹, Kosmidis P.⁴, Papadimitriou Ch.⁵, Murray S.⁶

¹A' Department of Oncology, Metropolitan Hospital, Athens, Greece, ²Medical School, Athens University, Greece,

³Department of Mathematics, Athens University and MRC Biostatistics Unit, Cambridge, UK, ⁴B' Department of Oncology, Hygeia Hospital, Athens, Greece, ⁵University Oncology Clinic, Alexandras Hospital, Athens, Greece,

⁶Department of Molecular Biology & Genetics, Metropolitan Hospital, Athens, Greece

O 10.

DESCRIBING THE EFFECTS OF CANCER TREATMENTS: PROGRESSION-FREE-SURVIVAL (PFS) IS MORE RELIABLE THAN TIME-TO-PROGRESSION (TPP)

Porzsolt F¹, Weber A.¹, Zajicek G.², Muche R.³

¹Clinical Economics, University of Ulm, Germany, ²Developmental Biology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem, Israel, ³Dept. Biostatistics and Medical Information, University of Ulm, Germany

14.30-16.00

L u n c h b r e a k

16.00-17.30

Proffered papers (Session II)

"Nursing and Supportive Care

Chairpersons: P. Papakostas (Greece), S. Roussakis (Greece)

O 11.

TREATMENT AND PREVENTION OF BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAWS

Papadopoulou E.¹, Nicolatou-Galitis O.¹, Karayianni A.², Kirtsoni C.³, Repousis P.⁴, Kokkini G.⁵, Barbounis V.⁶, Samadas E.⁷

¹Clinic of Hospital Dentistry, Dental Oncology Unit, School of Dentistry, University of Athens, Greece, ²Clinic of Oral Diagnosis and Radiology, School of Dentistry, University of Athens, Greece, ³Hospital «LAIKO», Hematological Clinic, Medical School, University of Athens, Greece, ⁴Anticancer Hospital «METAXA», Hematological Clinic, Piraeus, Greece,

⁵Hospital «SISMANOGLEIO», Hematological Clinic, Athens, Greece, ⁶Anticancer Hospital «Saint Savvas», Athens, Greece, ⁷Hospital «AGIOI ANARGYROI», Athens, Greece

O 12.

H ORAL MUCOSITIS, PAIN AND XEROSTOMIA IN PATIENTS WITH HEAD AND NECK CANCER WHO RECEIVED CHEMORADIOThERAPy WITH OR WITHOUT CETUXIMAB. A COMPARATIVE CLINICAL STUDY

Sarri T.¹, Nicolatou-Galitis O.¹, Polychronopoulou A.², Koukoulias V.³, Dardoufas K.⁴, Vakalis K.⁵, Demenagas D.⁶, Sotiropoulou-Lontou A.⁶

¹Clinic of Hospital Dentistry, Dental School, University of Athens, Greece, ²Department of Preventive and Community Dentistry, School of Dentistry, University of Athens, Greece, ³Department of Radiotherapy, «Attikon» Hospital, School of Medicine, University of Athens, Greece, ⁴Department of Radiotherapy, «Ygeia» Hospital, Athens, Greece, ⁵Department of Radiotherapy, «401 Hospital», Athens, Greece, ⁶2nd Radiotherapy Dpt, "Saint Savvas" Hospital, Athens, Greece



16.00-17.30

O 13.

EDUCATIONAL PROGRAM FOR NURSES ON PREVENTION AND MANAGEMENT OF CANCER TREATMENT INDUCED ORAL MUCOSITIS

Kav S., Borulday B.¹, Sergi C.¹, Goktan N.¹, Melek S.¹, Karaman Nu.²

¹Baskent University Faculty of Health Sciences, Department of Nursing, Ankara, Turkey, ²Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey

O 14.

XEROSTOMIA IN CANCER THERAPY: AETIOLOGY, ORAL/DENTAL SEQUELAE, TREATMENT AND PREVENTION

Nicolatou-Galitis O¹, Sotiropoulou-Lontou A.², Kouloulias V.³, Dardoufas K.⁴, Vakalis X.⁵, Kyprianou K.⁵, Georgakopoulos G.⁶, Pissakas G.⁷, Kolitsi G.⁸, Kouvaris J.⁴

¹School of Dentistry, Dental Oncology Unit, Greece, ²Saint Savvas Hospital, 2nd Radiotherapy Dpt, Athens, Greece,

³Attikon Hospital, Radiotherapy Dpt, Athens, Greece, ⁴Aretaeion Hospital, Radiotherapy Dpt, Athens, Greece,

⁵Euromedica, Radiotherapy Dpt, Athens, Greece, ⁶1st IKA, Radiotherapy Dpt, Athens, Greece, ⁷Alexandras Hospital, Radiotherapy Dpt, Athens, Greece, ⁸Hygeia Hospital, Radiotherapy Dpt, Athens Greece

O 15.

EFFICACY AND TOLERABILITY OF PALONOSETRON IN COMBINATION WITH APREPITANT AND DEXAMETHASONE IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY

Okutur K., Aydin K.¹, Bozkurt M.¹, Demir N.², Turan C.², Demir G.¹

¹Istanbul Bilim University, School of Medicine, Medical Oncology Department, Istanbul, Turkey, ²Istanbul Bilim University, School of Medicine, Internal Medicine Department, Istanbul, Turkey

O 16.

NEEDS OF GASTROINTESTINAL CANCER PATIENTS DURING AND AFTER TREATMENT IN GREECE

Heras P., Hatzopoulos A., Hera M., Xourafas V., Mantzioros M., Kritikos K.

Hellenic Medical Society for the Study of Psychosomatic Problems, Greece

O 17.

PSYCHOMETRIC EVALUATION OF THE GREEK PITTSBURGH SLEEP QUALITY INDEX (GR-PSQI) IN CANCER PATIENTS RECEIVING ACTIVE-PHASE TREATMENT

Kotronoulas G¹, Papadopoulou C.², Papapetrou A.³, Patiraki E.⁴

¹University of Stirling, Scotland, UK, ²«Attikon» University Hospital, University of Stirling, Scotland, UK, ³«Hygeia» Hospital, Athens, Greece, ⁴University of Athens, Greece

O 18.

IDENTIFYING SYMPTOM CLUSTERS IN PAEDIATRIC CANCER PATIENTS USING THE MEMORIAL SYMPTOM ASSESSMENT SCALE

Atay S., Conk Z.², Bahar Z.³

¹Hacettepe University, Ankara, Turkey, ²Ege University, Izmir, Turkey, ³Dokuz Eylul University, Izmir, Turkey

O 19.

FEMALE BREAST CANCER PATIENTS' BODY IMAGE ASSESSMENT

Psychogiyiou A¹, Giannakopoulou M.², Katsaragakis S.², Patiraki E.²

¹St Savas Cancer Hospital, Athens, Greece, ²Nursing Faculty, National and Kapodistrian University of Athens, Greece

O 20.

SELF-EFFICACY BELIEFS AND LEVELS OF ANXIETY IN ADVANCED CANCER PATIENTS

Parpa E¹, Mystakidou K.¹, Tsilika E.¹, Gogou P.², Theodorakis P.³, Vlahos L.²

¹Pain Relief and Palliative Care Unit, "Aretaeion" Hospital, Radiology Department, School of Medicine, University of Athens, Greece, ²"Aretaeion" Hospital, Radiology Department, School of Medicine, University of Athens, Greece,

³Health & Social Solidarity, Municipality of Athens, Greece

H
A
R
F
—



17.30-19.00	Symposium: "Cancer Prevention: reality or dream?" Chairpersons: E. Petridou (<i>Greece</i>), B. Berkarda (<i>Turkey</i>)	H A L I
17.30 - 17.50	Epidemiology and cancer prevention across the Mediterranean : differences and similarities S. Franceschi (<i>France</i>)	
17.50 - 18.10	Implementation of population screening programs: the challenge and the role of local governments N. Arber (<i>Israel</i>)	
18.10 - 18.30	Chemoprevention: where do we stand today? (breast, prostate Ca, colorectal) V. Vogel (<i>USA</i>)	
18.30 - 18.50	Mediterranean diet and cancer A. Trichopoulou (<i>Greece</i>)	
18.50 - 19.00	Discussion	
19.00-19.30	Keynote Lecture Chairpersons: S. Murray (<i>Greece</i>), M. Garassino (<i>Italy</i>) Molecular Oncology – the era of individualised cancer management? Y. Yarden (<i>Israel</i>)	H A L I
19.30	Depart for the Opening Ceremony to be held at the Acropolis Museum	
	H Opening Ceremony Chairpersons: D. Bafaloukos (<i>Greece</i>), A. Testori (<i>Italy</i>)	
20.30-21.00	Welcome Addresses	
21.00-22.00	Guided visit to the Acropolis Museum	
22.00	Welcome Reception at the Veranda of the Acropolis Museum Restaurant	

10.30 - 14.30	Oncology Nursing Symposium "Symptom Management in Oncology Patients: Nursing Perspectives" Chairpersons: E. Patiraki (Greece) – S. Kav (Turkey)	
10.30 - 10.40	Welcome and Introduction A. Tarampikou (Greece)	
10.40 - 11.00	Introduction Lecture Chairperson: E. Patiraki (Greece) Symptom management as a high research priority in oncology nursing S. Kav (Turkey)	H A L
11.00 - 12.00	Round Table Nursing Management of Patients with Difficult Physical Symptoms Chairpersons: Ch. Lemonidou (Greece), D. Papageorgiou (Greece)	A L
11.00 – 11.15	<ul style="list-style-type: none"> • Fatigue A. Yaffe (Israel)	
11.15 – 11.30	<ul style="list-style-type: none"> • Pain P. Fernandez-Ortega (Spain)	
11.30 – 11.45	<ul style="list-style-type: none"> • Breathlessness S. Katsaragakis (Greece)	
11.45 – 12.00	<ul style="list-style-type: none"> • Nausea – Vomiting A. Charalambous (Cyprus)	
12.00 – 12.15	<ul style="list-style-type: none"> • Alopecia A. Milani (Italy)	
12.15 – 12.30	Discussion	
12.30-13.00	C o f f e e b r e a k	
13.00 – 13.15	Lecture Chairperson : A. Psychogiou (Greece) Symptoms' Psychological Effects : How to Help Patients Develop Coping Strategies G. Balaska (Greece)	
13.15 – 13.30	Lecture Chairperson: A. Papadouri (Greece) Symptom Cluster: The New Frontier in Symptom Management S. Atay (Turkey)	H A L
13.30 – 14.30	Discussion Forum. Relieving Physical and Emotional Burden of Cancer Patients: Mediterranean Countries Reality and Vision Chairpersons: D. Pappa (Greece), F. Gundogdu (Turkey) <ul style="list-style-type: none"> • Cyprus: A. Charalambous • Greece: Ch. Karlou • Israel: A. Yaffe • Italy: A. Milani • Spain: P. Fernandez-Ortega • Turkey: K. Aysin 	
14.30-16.00	L u n c h b r e a k	



09.00-14.30	BREAST CANCER DAY (Organized by Roche Hellas)	H A L L I
09.00-10.30	"Deconstructing" breast cancer	
—	Chairpersons: P. Kosmidis (Greece), G. Asimakopoulos (Greece)	
09.00-09.10	Breast Cancer Day 2009: Leading our expectations	
—	P. Kosmidis (Greece)	
09.10-09.30	"Breast cancer awareness in Greece: Where do we stand today?"	
—	I. Tountas (Greece)	
09.30-10.00	"Current dilemmas in the treatment of breast cancer"	
—	A. Efremidis (Greece)	
10:00-10.30	"Evolution of breast cancer therapy: The revolution of targeting agents"	
	Ch. Sotiriou (Belgium)	
10.30-11.00	C o f f e e b r e a k	
11.00-12.00	EBC session "Setting the treatment perspectives in early breast cancer" Chairpersons: K. Syrigos (Greece), G. Xepapadakis (Greece)	
11:00-11.20	"Pursuing accuracy of HER2 testing" G. Viale (Italy)	
11:20-11.50	"Chance for cure in Early Breast Cancer" P. Ellis (UK)	
11:50-12.00	Discussion	
12:00-13.10	MBC session "Prolonging survival in the treatment of metastatic breast cancer" Chairpersons: D. Pectasides (Greece), S. Kakolyris (Greece)	
12:00-12.30	"Advancing the treatment landscape of HER2 positive patients" P. Fumoleau (France)	
12:30-13.00	"Controlling angiogenesis - Transforming the treatment landscape of HER2 negative patients" Ch. Zielinski (Austria)	
13:00-13.10	Discussion	
13:10-14.00	"Treating breast cancer in daily practice" Chairpersons: A. Efremidis (Greece), Ch. Zielinski (Austria)	
13:10-13.25	Early breast cancer in daily practice (case study) H. Gogas (Greece)	
13:25-13.40	HER2 positive metastatic breast cancer in daily practice (case study) E. Razis (Greece)	
13:40-13.55	HER2 negative metastatic breast cancer in daily practice (case study) I. Yücel (Turkey)	
13:55-14.10	Discussion	
14:10-14.30	"Reconstructing" breast cancer: Take home messages in 2009 and beyond A. Efremidis (Greece)	
14:30-16:00	L u n c h B r e a k	
15:00-16:00	Poster Discussion Session Chairpersons: S. Zervoudis (Greece), I. Navrozoglou (Greece), C. Christodoulou (Greece)	



16.00-18.00	Symposium: "Hot Topics and Challenges in Lung Cancer" Chairpersons: G. Tortora (<i>Italy</i>), A. Demirkazik (<i>Turkey</i>)
16.00-16.20	New developments in staging of NSCLC M. Douzinas (<i>Greece</i>)
16.20-16.35	Unanswered questions in early-stage disease <i>thoracic surgeon: K. Kaynak</i> (<i>Turkey</i>)
16.35-16.50	medical oncologist: M. Garassino (<i>Italy</i>)
16.50-17.10	Optimal systemic treatment and sequence in advanced disease E. Briasoulis (<i>Greece</i>)
17.10-17.30	Is Lung Adenocarcinoma one disease? (<i>molecular stratification of lung cancer, EGFR, TKIs and mutations: where do we stand today?</i>) S. Viteri (<i>Spain</i>)
17.30-17.50	SCLC: any progress? R. Gaafar (<i>Egypt</i>)
17.50-18.00	Discussion
18.00-18.30	Coffee break
18:30-20.30	Satellite Symposium I "ERBITUX : A Step forward to personalised Cancer Medicine" Chairpersons: P. Kosmidis (<i>Greece</i>), D. Skarlos (<i>Greece</i>)
18:30 - 18:35	Introduction
18:35 - 19:10	NSCLC: Increasing Survival in 1 st Line NSCLC L. Crino (<i>Italy</i>)
19:10 - 19:45	CRC: The first line targeted therapy for mCRC D. Papamichael (<i>Cyprus</i>)
19:45-20:20	SCCHN: New Breakthrough in History of Head and Neck Cancer A. Psirri (<i>Greece</i>)
20:20- 20:30	Conclusions

HALL III

H A L L I	
16.00-17.30	Workshop I: "Innovations in Breast Cancer Surgery"
16.00-16.40	1. Sentinel Lymph Node Chairperson: D. Tsiftsis (<i>Greece</i>)
16.00-16.30	Sentinel Lymph Node biopsy in early breast cancer: the philosophy P. Veronesi (<i>Italy</i>)
16.30-16.40	Discussion
16.40-17.30	2. In situ breast carcinoma Chairpersons: G. Zografos (<i>Greece</i>), F. Poulakaki (<i>Greece</i>)
16.40-17.00	DCIS: novel approaches G. Vlastos (<i>Switzerland</i>)
17.00-17.20	LCIS: what do we know today I. Askoxilakis (<i>Greece</i>)
17.20-17.30	Discussion
18.00-18:30	Coffee break

POSTERS

Chairpersons: C. Christodoulou (Greece), S. Zervoudis (Greece), I. Navrozoglou (Greece)

CLINICAL RESEARCH (PO 1-PO 29)

P 01.

MANAGEMENT OF INTRACTABLE ASCITES BY PERITONEO-VENOUS (LEVEENTM) SHUNT

Pologeorgis G.¹, Orfanidou M.¹, Horianopoulou E.¹, Plaitakis G.², Paraskevas E.³

¹Third Surgical Department, Saint Savas Cancer Hospital, Athens, Greece, ²Department of Anesthesiology, Saint Savas Cancer Hospital, Athens, Greece, ³Department of Gastroenterology, Saint Savas Cancer Hospital, Athens, Greece

P 02.

INVESTIGATE AND RECORD THE MOST FREQUENT DEVELOPING PATHOGENS IN PATIENTS SUFFERING FROM CANCER, IN LATE STAGES

Patiakas S.¹, Barbantonakis N.², Xanthakis I.³

¹General Hospital of Kastoria, Greece, ²General Hospital of Hellenic Air Force, Greece, ³General Hospital of Thessaloniki "Papageorgiou", Greece

P 03.

COMPLETE REMISSION OF A MESENTERIC LIPOSARCOMA WITH TRABECTIDIN

Tsoukalas N.¹, Papakostidi A.¹, Iydas G.¹, Papadimitriou C.¹, Pistamalantzian N.¹, Panopoulos C.¹, Demiri S.¹, Kourmakis G.¹, Barbounis V.¹, Efremidis A.¹

¹2nd Department Clinical Oncology, "Saint Savvas" Anticancer Hospital, Athens, Greece

P 04.

SURGICAL TREATMENT OF SYNCHRONOUS MULTIFOCAL CANCER OF THE LUNG AND OTHER SITES

Garmpis D.¹, Pigis A.¹, Petraki K.², Douzinas M.¹

¹Metropolitan Hospital, Thoracic Surgery Department, Athens, Greece, ²Metropolitan Hospital, Pathology Department, Athens, Greece

P 05.

EVALUATION OF INTRAVENOUS ZOLENDRONIC ACID (ZA) 4 MG IN GASTRIC CANCER PATIENTS (GC) WITH BONE METASTASIS

Heras P.¹, Kritikos K.¹, Hatzopoulos A.¹, Heras V.¹, Kritikos D.¹

¹Hellenic Medical Society for the Study of Psychosomatic Problems, Greece

P 06.

H INTRAOPERATIVE RADIATION THERAPY (IORT) IN ADVANCED OR RECURRENT HEAD AND NECK CANCER

Kyrgias G.¹, Masouris G.¹, Doumas S.¹, Papagianni M.¹, Kigitzi E.¹, Papamanthos M.¹, Kolokotronis A.¹, Rapidis A.¹

¹University Hospital of Larissa, Larissa, Greece

P 07.

ORAL LANGERHANS CELL HISTIOCYTOSIS: A CASE REPORT

Sarri T.¹, Galiti D.¹, Papadaki T.², Fisfis M.³, Nicolatou-Galitis O.¹

¹Clinic of Hospital Dentistry, Dental School, University of Athens, Greece, ²Hemopathology Department, Evangelismos Hospital, Athens, Greece, ³Clinic of Hematology, Amalia Fleming Hospital, Athens, Greece

P 08.

MANAGEMENT OF PRIMARY NEUROENDOCRINE CARCINOMA OF THE BREAST

Yildirim Y.¹, Elagoz S.², Koyuncu A.³, Aydin C.³, Karadayi K.³

¹Sivas Numune Hospital, Medical Oncology Department, Sivas, Turkey, ²Cumhuriyet University, Department of Pathology, Sivas Turkey, ³General Surgery Department, Sivas, Turkey

P 09.

TRASTUZUMAB PLUS CAPECITABINE AND DOCETAXEL AS FIRST LINE THERAPY FOR METASTATIC BREAST CANCER

Michalaki V.¹, Gennatas S.¹, Fotiou S.¹, Gennatas C.¹

¹Oncology Clinic, Areteion Hospital, University of Athens, Greece

P 10.

MULTIPLE MYELOMA IN EASTERN PART OF LIBYA: A RETROSPECTIVE ANALYSIS

Elsahati M.¹, Hawill A.¹, Guweidhi A.¹, Latewish M.¹, Elmangouish M.¹

¹Hematology department, Al Jamahiyria Teaching Hospital, Benghazi, Libya

H
A
L
I
—
—
—
—



P 11.

THE EFFECT OF COMBINED CHEMOTHERAPY WITH PACLITAXEL, CARBOPLATIN AND CAPECITABINE (PCC) IN METASTATIC GASTRIC CANCER

Matsiakou F.¹, Res E.¹, Grech M.¹, Stavridimou A.¹, Boutsikou M.¹, Papakostas P.¹

¹Department of Oncology, "Hippocratio" Hospital, Athens, Greece

P 12.

RETROSPECTIVE ANALYSIS OF 64 MALIGNANT MESOTHELIOMA PATIENTS

Dogan M.¹, Yalcintas Arslan U.², Utukan G.¹, Ozal G.¹, Demirkazik A.¹, Akbulut H.¹, Yalcin B.¹, Buyukcelik A.¹, Alkis N.², Onur H.¹, Icli F.¹

¹Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey, ²Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey

P 13.

FIFTY-ONE PATIENTS WITH KAPOSI SARCOMA

Dogan M.¹, Dogan L.², Ozdemir F.³, Yildirim Ozdemir N.⁴, Senol Coskun H.⁵, Yalcintas Arslan U.⁶, Ozal G.¹, Utukan G.¹, Demirkazik A.¹, Aydin F.³, Zengin N.⁴, Icli F.¹

¹Ankara University, School of Medicine, Department of Medical Oncology, Ankara, Turkey, ²Ankara Oncology Education and Research Hospital, Department of General Surgery, Ankara, Turkey, ³Karadeniz Technical University, School of Medicine, Department of Medical Oncology, Turkey, ⁴Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey, ⁵Akdeniz University, School of Medicine, Department of Medical Oncology, Turkey, ⁶Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey

P 14.

RETROSPECTIVE ANALYSIS OF SEVENTY-ONE PATIENTS WITH NEUROENDOCRINE TUMORS

Dogan M.¹, Yildirim Ozdemir N.², Yalcintas Arslan U.³, Dogan L.⁴, Ozal G.¹, Utukan G.¹, Yalcin B.¹, Demirkazik A.¹, Akbulut H.¹, Zengin N.³, Alkis N.³, Icli F.¹

¹Ankara University, School of Medicine, Department of Medical Oncology, Ankara, Turkey, ²Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey, ³Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey, ⁴Ankara Oncology Education and Research Hospital, Department of General Surgery, Ankara, Turkey

P 15.

CLINICOPATHOLOGICAL STUDY OF 17 PATIENTS WITH LARGE-CELL NEUROENDOCRINE TUMORS OF THE LUNG

Vaslambatzis M.¹, Papaxoinis G.¹, Vamvouka C.², Patila E.¹, Alevizopoulos N.¹, Tsiga A.², Ntelaki A.¹, Karra P.²,

Zisis C.³, Mouzakiti A.¹, Karathanasi A.¹, Exarchos D., Stathopoulos C.¹, Zoumblios C.¹, Skoula A.⁴, Bellenis I.³

¹Department of Oncology, Evangelismos General Hospital, Athens, Greece, ²Department of Pathology, Evangelismos General Hospital, Athens, Greece, ³Department of Thoracic Surgery, Evangelismos General Hospital, Athens, Greece, ⁴Department of Computed Tomography, Evangelismos General Hospital, Athens, Greece

P 16.

EXTRAABDOMINAL LYMPH NODE METASTASES: THE LATEST EVENT IN THE NATURAL HISTORY OF THE GASTROINTESTINAL STROMAL TUMORS (GISTS)

Vassos N.¹, Agaimy A.², Goehl J.¹, Hohenberger W.¹, Croner R.¹

¹Department of Surgery, University Hospital, Erlangen, Germany, ²Institute of Pathology, University Hospital, Erlangen, Germany

P 17.

NON-PULMONARY SMALL CELL CARCINOMAS

Tsoukalas N.¹, Papakostidi A.¹, Lypas G.¹, Papadimitriou C.¹, Pistamalntzian N.¹, Panopoulos C.¹, Demiri S.¹, Kourakis G.¹, Barbounis V.¹, Efremidis A.¹

¹2nd Department of Clinical Oncology, "Saint Savvas" Anticancer Hospital, Athens, Greece

P 18.

SQUAMOUS CELL CARCINOMA OF THE LUNG WITH ANAL CANAL METASTASIS

Okutur K.¹, Arslan K.¹, Bozkurt M.¹, Barlan M.², Oz B.³, Demir G.¹

¹Istanbul Bilim University, School of Medicine, Department of Medical Oncology, Istanbul, Turkey, ²Gayrettepe Florence Nightingale Hospital, Department of Radiology, Turkey, ³Istanbul University Cerrahpasa School of

P 19.

DIFFUSE CAVERNOUS HEMANGIOMA OF THE RECTOSIGMOID COLON

Aktas E.¹, Ciledag N.¹, Demir Gumusdag P.¹, Arda K.¹

¹Department Of Radiology, Ankara Oncology Training And Research Hospital, Ankara, Turkey

H
A
R
L
—
—
—
—
—
—



P 20.

MALIGNANT OVARIAN GERM CELL TUMORS: A SINGLE-INSTITUTION EXPERIENCE.

Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., Tuzlali S., Gorgun O., Topuz E.

From the *Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne; Departments of daggerMedical Oncology and double daggerPediatric Oncology, Institute of Oncology, Obstetrics and Gynecology, and paragraph signPathology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.

P 21.

PENILE METASTASIS FROM TRANSITIONAL CELL CARCINOMA OF THE BLADDER

Kantzou I.^{1,2}, Sarris G.², Kouloulias V.¹

¹Athens University, Medical School, ²Department Radiology, Radiotherapy Unit, Attikon Hospital, Athens, Greece,

²Metaxa Hospital, Radiotherapy Department, Athens, Greece

P 22.

FIRST LINE CHEMOTHERAPY WITH THE COMBINATION OF CISPLATIN – VINBLASTINE – TEMOZOLOMIDE (PVT) IN PATIENTS WITH METASTATIC MELANOMA

Panagiotakou A.¹, Tarampikou A.¹, Linardou H.¹, Kanaloupiti D.¹, Molfeta A.¹, Bousbouka E.¹, Karkadaris Ch.¹, Giannopoulos V.¹, Lazaridis G.¹, Bafaloukos D.¹

¹1st Oncology Department, Metropolitan Hospital, Athens, Greece

P 23.

PRIMARY CANCER OF BREAST AND ITS INCOMPATIBILITY BETWEEN HORMONE RECEPTOR STATUS AND HER-2 LEVEL IN METASTASIS TO THE LIVER: A CASE REPORT

Uyeturk U.¹, Arpacı E.¹, Yalcintas Arslan U.¹

¹Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, Clinical of Medical Oncology, Ankara, Turkey

P 24.

SMALL BOWEL PERFORATION DUE TO BEVACIZUMAB THERAPY IN METASTATIC CARCINOMA, A CASE REPORT

Uyeturk U.¹, Pelin Demir R.², Arda K.², Uysal Sonmez O.¹, Yalcintas Arslan U.¹

¹Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, Clinical of Medical Oncology, Ankara, Turkey, ²Dr.

Abdurrahman Yurtaslan Oncology Education and Research Hospital, Clinical of Radiology, Ankara, Turkey

P 25.

PLEURAL EFFUSION SEEN IN PRIMARY PULMONARY MALT LYMPHOMA, A CASE REPORT

Usul Afsar C.¹, Uyeturk U.², Arda K.³

¹Istanbul Education and Research Hospital, Clinical Of Internal Medicine, Istanbul, Turkey, ²Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, Clinical of Medical Oncology, Ankara, Turkey, ³Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, Clinical of Radiology, Ankara, Turkey

P 26.

SENTINAL LYMPH NODE BIOPSY FOR THE BREAST CANCER PATIENTS DIAGNOSED WITH EXCISIONAL BIOPSY

Coskun G.¹, Ozaslan C.¹, Karaman N.¹, Dogan L.¹, Atalay C.¹

¹Department of Surgery, Ankara Oncology Training and Research Hospital, Ankara, Turkey

P 27.

EARLY POSTOPERATIVE COMPLICATIONS AFTER MAMMOPLASTY SURGERY

Dogan L.¹, Karaman N.¹, Kiziltan G.¹, Ozaslan C.¹, Atalay C.¹

¹Department of Surgery, Ankara Oncology Training and Research Hospital, Ankara, Turkey

P 28.

ONCOPLASTIC PROCEDURES: THE MODERN APPROACH TO THE SURGERY OF THE BREAST

Poulakaki N.¹, Sarakinou E.¹, Demestiha T.¹, Chrelia C.¹, Sykiotis C.¹, Makris G.¹, Salamalekis G.¹, Salamalekis E.¹

¹Attikon Hospital 3rd Department Of Obstetrics And Gynecology, Metropolitan Hospital, Athens, Greece

P 29.

COMPARATIVE STUDY OF RECURRENCE USING COMPLEMENTARY TREATMENT WITH POLITIMOD AFTER LASER FOR GENITAL WARTS AND CIN

Zervoudis S^{1,2}, Iatrakis G², Peitsidis P¹, Peitsidou A³, Papandonopoulos L¹, Nikolopoulou M.K¹,

Papadopoulos L¹

¹"Lito" Hospital, Athens, Greece, ²TEI Technn.University of Athens, Greece, ³"Alexandra" Hospital, Athens, Greece

H
A
L
—
—
—
—



TRANSLATIONAL RESEARCH (P30-P39)

P 30.

IS SKI PROTEIN EXPRESSION AN INDEPENDENT PROGNOSTIC FACTOR IN INVASIVE BREAST CARCINOMAS?

Theohari L.¹, Giannopoulou I.¹, Magkou C.¹, Melissaris S.¹, Alexandrou P.¹, Papadimitriou C.², Dimopoulos A.², Nakopoulou L.¹

¹1st Department of Pathology, Medical School, University of Athens, Greece, ²Department of Clinical Therapeutic, Medical School, University of Athens, Greece

P 31.

RADIOISOTOPE CEREBROSPINAL FLUID FLOW STUDY IN PATIENTS WITH LEPTOMENINGEAL METASTASES

Pianou N.¹, Plataniotis N.¹, Vasilaki-Antonatou M.¹, Anagnostopoulos K.¹, Theodosopoulos P.¹, Kalogeropoulos K.¹, Vonorta K.¹, Tsilomeleti E.¹

¹Nuclear Medicine Departments, Group IASO Hospital, Greece

P 32.

PROLIFERATIVE CELL NUCLEAR ANTIGEN IN PATIENTS WITH BREAST CANCER

Garanina Z.¹, Hadjiolov N.¹, Piperkova E.¹, Velikova C.¹

¹National Cancer Hospital Sofia, Bulgaria

P 33.

NON-SMALL CELL LUNG CANCER (NSCLC): INFLUENCE OF AROMATASE AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS

Giannopoulou E.¹, Kritikou I.¹, Koutras A.¹, Kalofonos Ch.¹

¹Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, Greece

P 34.

THE PRESENCE OF AN INTRON 8 POLYMORPHISM OF NFkB 2 MAY PREDISPOSES TO NSCLC.

Dimitrakopoulos F.¹, Antonacopoulou A.¹, Maroussi S.¹, Kottorou A.¹, Scopa C.², Kalofonos Ch.¹

¹Clinical Oncology Laboratory, Medical School, University of Patras, Rio, Greece, ²Department of Pathology, Medical School, University of Patras, Rio, Greece

P 35.

H ORAL LESIONS AND ORAL TUMORS STRONGLY ASSOCIATED WITH HIV INFECTION AND CD4(+) LYMPHOCYTE COUNT IN ANTIRETROVIRAL THERAPY (ART)-NAIVE PATIENTS. A PRELIMINARY REPORT

Nicolatou-Galitis O.¹, Sarri T.¹, Sambatakou H.¹

¹School of Dentistry & School of Medicine, University of Athens, Greece

P 36.

CHANGES IN LYMPHOCYTIC POPULATIONS AND AUTOANTIBODIES RESULTING FROM SUNITINIB TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)

Karadimou A.¹, Gavalas N.¹, Sereti E.¹, Gyftaki R.¹, Lainakis G.¹, Dimopoulos A.¹, Bamias A.¹

¹Department of Clinical Therapeutics, University of Athens, Immunology Department, Alexandra Hospital, Athens, Greece

P 37.

THE mRNA EXPRESSION OF VEGF-A HAS PROGNOSTIC SIGNIFICANCE IN BREAST CANCER: STUDY IN PRIMARY TUMOURS OF PATIENTS WITH HIGH RISK EARLY BREAST CANCER PARTICIPATING IN A PROSPECTIVE RANDOMIZED STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG).

Linardou H.¹, Briassoulis E.¹, Kalogerias K.¹, Wirtz RM.², Gogas H.¹, Pectasides D.¹, Aravantinos G.¹, Papakostas P.¹, Kalofonos Ch.¹, Eleftheraki A.¹, Bafaloukos D.¹, Skarlos DV.¹, Fountzilas G.¹

¹Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece, ²Siemens Healthcare Diagnostics, Cologne, Germany

P 38.

SOMATIC MUTATIONS OF EGFR AND KRAS IN CHOLANGIOCARCINOMAS. A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY.

Murray S.¹, Samantas E.¹, Linardou H.¹, Bobos M.¹, Fountzilas G.¹, Tsavoutsa S.¹, Rontogianni D.¹, Dervenis Ch.¹, Briassoulis E.¹, Kalofonos Ch.¹, Skopa Ch.¹, Kabosioras K.¹, Christodoulou Ch.¹, Bafaloukos D.¹

¹Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece

H
A
R
—
—
—
—
—
—
—
—



P 39.

PREDICTIVE AND PROGNOSTIC SIGNIFICANCE OF SOMATIC MUTATIONS IN THE TYROSINE KINASE (TK) DOMAIN OF EGFR IN NSCLC PATIENTS TREATED WITH SINGLE AGENT GEFITINIB: A SYSTEMATIC REVIEW AND META-ANALYSIS

Murray S.¹, Evangelou E.², Linardou H.³, Bafaloukos D.³, Kosmidis P.⁴, Ioannidis J.²

¹Department of Molecular Biology & Genetics, Metropolitan Hospital, Athens, Greece, ²University of Ioannina, Ioannina, Greece, ³First Department of Oncology, Metropolitan Hospital, Athens, Greece, ⁴Second Department of Oncology, Hygeia Hospital, Athens, Greece

NURSING AND SUPPORTIVE CARE (P40-P49)

P 40.

FACING CANCER: STUDY OF DEMEANOUR, EMOTIONS AND RESPONSE OF PATIENTS WITH MALIGNANCIES THROUGH THE COURSE OF THEIR DISEASE

Xanthakis I.¹, Patiakas S.², Barbantidakis N.³

¹General Hospital of Thessaloniki "Papageorgiou", Greece, ²General Hospital of Kastoria, Greece, ³General Hospital of Hellenic Air Force, Greece

P 41.

EVALUATION OF PALONOSETRON AND ALPRAZOLAM AGAINST VOMITING CAUSED BY CHEMOTHERAPY IN PATIENTS WITH GASTRIC CANCER

Heras P.¹, Kritikos K.¹, Hatzopoulos A.¹, Heras V.¹, Kritikos D.¹

¹Hellenic Medical Society for the Study of Psychosomatic Problems, Greece

P 42.

THE EFFECT OF SELF-CARE PROGRAMS ON PSYCHO-SOCIAL AND COGNITIVE FUNCTIONING OF COLORECTAL CANCER (CC) PATIENTS

Heras P.¹, Hatzopoulos A.¹, Hera M.¹, Kritikos N.¹, Xourafas V.¹, Karagiannis S.¹, Mantzioros M.¹, Kritikos K.¹

¹Hellenic Medical Society for the Study of Psychosomatic Problems, Greece

P 43.

"SEXUALITY-RELATED PROBLEMS IN GREEK CANCER PATIENTS: A DESCRIPTIVE, CORRELATIONAL STUDY"

Kotronoulas G.¹, Papadopoulou C.²

¹University of Stirling, Scotland, UK, ²"Attikon" University Hospital, University of Stirling, Scotland, UK

P 44.

SELF ASSESSMENT OF QUALITY OF LIFE IN GREEK CANCER PATIENTS AT HOME

Adamakidou T.¹, Zlovotska M.², Delidakis A.³, Katostaras T.⁴, Kalergis G.⁴, Kalokerinou A.⁴

¹"St Savvas" Anticancer Hospital, Greece, ²Home Health Care Unit, "Metaxa" Anticancer Hospital, Greece, ³Home Health Care Unit, "St. Anargiri" Anticancer Hospital, Greece, ⁴Faculty of Nursing, University of Athens, Greece

P 45.

QUALITY OF LIFE EVALUATION: WHEN DO CANCER PATIENTS AT HOME AND HEALTH CARE NURSES AGREE?

Adamakidou T.¹, Kapsali E.², Makris N.³, Katostaras T.⁴, Kalergis G.⁴, Kalokerinou A.⁴

¹"St Savvas" Anticancer Hospital, Greece, ²Home Health Care Unit, "Metaxa" Anticancer Hospital, Greece, ³Home Health Care Unit, "St. Anargiri" Anticancer Hospital, Greece, ⁴Faculty of Nursing, University of Athens, Greece

P 46.

ORAL MUCOSITIS, PAIN AND XEROSTOMIA IN 135 HEAD AND NECK CANCER PATIENTS RECEIVING RADIOTHERAPY WITH OR WITHOUT CHEMOTHERAPY

Nicolatou-Galitis O.¹, Koukoulias V.², Sotiropoulou-Lontou A.³, Dardoufas K.⁴, Polychronopoulou A.⁵,

Athanassiadou P.⁶, Kolitsi G.⁴, Kouvaris J.⁷

¹Dental Oncology Unit, Clinic of Hospital Dentistry, School of Dentistry, University of Athens, Greece, ²Department of Radiotherapy, "Attikon" University Hospital, Athens, Greece, ³2nd Radiotherapy Department, "Saint Savvas" Anticancer Hospital, Athens, Greece, ⁴Radiation Oncology Department, "Hygeia" Hospital, Athens, Greece, ⁵Department of Preventive and Community Dentistry, School of Dentistry, University of Athens, Greece, ⁶Department of Pathologic Anatomy, School of Medicine, University of Athens, Greece, ⁷Department of Radiotherapy, "Aretaeion" University Hospital, School of Medicine, University of Athens, Greece

H
A
L
—
—
—



P 47.

THE INCIDENCE OF PLACE OF DEATH IN GREEK CANCER PATIENTS IN 1995 AND 2005

Panagiotou I.¹, Mystakidou K.¹, Parpa E.¹, Tsilika E.¹, Galanos A.¹, Tsiatas M.², Theodorakis P.³

¹*Pain Relief and Palliative Care Unit, "Areteion" Hospital, Radiology Dep., School of Medicine, University of Athens, Greece,*

²*Department of Clinical Therapeutics "Alexandra" Hospital, School of Medicine, University of Athens, Greece,*

³*Health & Social Solidarity, Municipality of Athens, Greece*

P 48.

COMPLIANCE WITH ORAL ANTICANCER AGENTS: SINGLE CENTER PROSPECTIVE COHORT

ANALYSIS

Tarampikou A.¹, Linardou H.¹, Kanaloupi D.¹, Panagiotakou A.¹, Balaska G.¹, Giannopoulos V.¹, Ioannoglou P.¹,
Efthimiou S.¹, Zisiopoulou H.¹, Bafaloukos D.¹

¹*1st Department of Oncology, Metropolitan Hospital, Athens, Greece*

H

P 49.

ILLNESS PERCEPTION AND HOPELESSNESS LEVELS IN CANCER PATIENTS

Aysin K.¹

¹*Acibadem Kozyatağı Oncology Hospital, Istanbul, Turkey*

H
A
L
L
—
—



08.30-10.00	Young Oncologists Breakfast "Practical Aspects for an Oncology Career" Chairpersons: M. Karamouzis (Greece), P. Saip (Turkey)	
	Speakers: D. Bafaloukos, introductory remarks (Greece) S. Jezdic (ESMO Head Office) B. Besse (France) J. Mountzios (Greece) M. Ignatiadis (Belgium)	
10:00-14:00	GI Cancer Symposium: "Hot topics and Challenges in colorectal, gastric and hepatobiliary cancer" Chairpersons: B. Klein (Israel), G. Pentheroudakis (Greece)	
10.00-10.20	Gastric Cancer: a common enemy across eastern Mediterranean-differences and similarities with western countries S. Yalcin (Turkey)	
10.20-10.40	Hepatocellular Cancer – where do we stand today? A. Beqiri (Albania)	
10.40-11.00	Current standards and options in the treatment of locally advanced pancreatic Ca S. Pleština (Croatia)	
11.00-11.10	Discussion	
11.10-11.30	Coffee break	H A L L
11.30-13.00	"Colorectal Cancer Session" Chairpersons: G. Demir (Turkey), G. Rostini (Italy)	
11.30-11.50	State-of-the-art strategies in 1 st line treatment of colorectal cancer F. Loupakis (Italy)	
11.50-12.10	The role of k-ras in colorectal cancer F. Di Nicolantonio (Italy)	
12.10-12.30	Optimal duration of treatment and the role of consolidation in advanced colorectal cancer D. Papamichael (Cyprus)	
12.30-12.50	The importance of angiogenesis in GI cancer and its therapeutic inhibition JL. Mayordomo (Spain)	
12.50-13.00	Discussion	
13.00-14.00	"Multidisciplinary management of rectal cancer - case discussions" Moderators: G. Androulakis (Greece), J.B. Dubois (France)	
13.00-13.15	Case 1: Surgeon G. Tsiotos (Greece)	
13.15-13.30	Case 2: Radiation Oncologist D. Kardamakis (Greece)	
13.30-13.45	Case 3: Med. Oncol. T. Bouzid (Tunisia)	
13.45-14.00	Discussion – Closing remarks	
14.00-15.00	Satellite Symposium II "The role of mTOR inhibition in different tumor types" Chairpersons: D. Bafaloukos (Greece), Ch. Kalofonos (Greece)	
	Current and future perspectives of Everolimus in metastatic Renal Cell Cancer C. Porta (Italy)	
	Recent advances in the NET management: targeting the mTOR pathway H. Athanasiadis (Greece)	
15.00-16:00	Lunch break	H A L L

Organized by Novartis Hellas



scientific programme • Saturday, September 12, 2009

16:00-17:30	Symposium: "Supportive therapy: implications from recent advances"	H A L L 
16.00-16.30	Lecture Chairpersons: O. Galitis-Nicolatou (<i>Greece</i>), A. Karagianni (<i>Greece</i>)	
16.30-17.30	Oral Supportive Oncology D. Peterson (<i>USA</i>)	
16.30-16.50	Chairpersons: D.V. Skarlos (<i>Greece</i>), S. Elad (<i>Israel</i>)	
16.50-17.10	Erythropoietin: the role in cancer anaemia P. Kottaridis (<i>UK</i>)	
17.10-17.30	Changing spectrum of infections in patients with neoplasia G. Samonis (<i>Greece</i>)	
	Handling side effects of novel targeted agents G. Aravantinos (<i>Greece</i>)	
17:30-18:00	Coffee break	
18:00-20:00	Multidisciplinary Symposium: "Improving cancer research and care" Chairpersons: P. Kosmidis (<i>Greece</i>), H. Onat (<i>Turkey</i>)	H A L L 
18.00-18.15	Inequalities in access to cancer care (the MOSES report) H. Linardou (<i>Greece</i>)	
18.15-18.30	Patient access to new anti-cancer agents A. Adamou (<i>Cyprus</i>)	
18.30-18.45	Health economics in oncology (or "the cost of cancer") N. Maniadakis (<i>Greece</i>)	
18.45-19.00	Discussion - remarks	
19.00-19.15	Cancer networks, centralisation of resources- the need for reference centres P. Casali (<i>Italy</i>)	
19.15-19.30	Funding for research across the Mediterranean and worldwide D. Thanos (<i>Greece</i>)	
19.30-19.45	Tumour Banks: biological material banking in Europe and the Mediterranean C. Chabannon (<i>France</i>)	
19.45-20.00	Discussion – closing remarks	
20:00-20:30	Awards – Closing ceremony Chairpersons: D. Bafaloukos (<i>Greece</i>), P. Saip (<i>Turkey</i>)	
21:00	Gala Dinner	



08:30-10:00

Proffered papers (session III)

"Clinical Research"

Chairpersons: A. Christopoulou (Greece) – S. Shamaa (Egypt)

O 21.

YOLK SAC TUMOURS OF THE OVARY: EVALUATION OF CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC FACTORS.

Cicin I¹, Saip P¹, Guney N¹, Eralp Y¹, Ayan I¹, Kebudi R¹, Topuz E¹

¹ Trakya University, Faculty of Medicine, Department of Medical Oncology, Turkey.

O 22.

POSTMASTECTOMY IRRADIATION IN BREAST CANCER PATIENTS WITH 1-3 POSITIVE AXILLARY LYMPH NODES: IS THERE A ROLE FOR RADIATION THERAPY?

Cosar-Alas R¹, Uzal C¹, Denizli B¹, Saynak M¹, Turan N³, Uzunoglu S², Karagol H², Tokatli F¹, Ibis K¹, Ozen A., Uregen B¹, Yurut-Caloglu V¹, Kocak Z¹

¹Department of Radiation Oncology, Trakya University, Faculty of Medicine, Edirne, Turkey, ²Department of Medical Oncology, Trakya University, Faculty of Medicine, Edirne, Turkey, ³Department of Biostatistics, Trakya University, Faculty of Medicine, Edirne, Turkey

O 23.

18 FDG-PET UPSTAGES PATIENTS WITH N2 NSCLC

Skoura E¹, Giannopoulou C¹, Houssianakou E¹, Vezyrgianni A¹, Drougas D¹, Skilakaki M¹, Datseris I¹

¹Nuclear Medicine and Radiology Department, «Evangelismos» Hospital, Athens, Greece

O 24.

PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL AND CARBOPLATIN IN PATIENTS WITH STAGE IIIB-IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER:

PRELIMINARY RESULTS

Papaxoinis G¹, Skondra M¹, Briassoulis E², Skarlos D³, Linardou E⁴, Lampaki S⁵, Polychronidou G⁵, Pectasides D¹

¹Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, "Attikon" University Hospital, Athens, Greece, ²Department of Medical Oncology, Ioannina University, Ioannina, Greece, ³Second Department of Medical Oncology, "Metropolitan" Hospital, Faliro, Greece, ⁴Department of Oncology, "Metropolitan" Hospital, Faliro, Greece, ⁵Department of Medical Oncology, «Papageorgiou» Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

H
A
R
—
—
H

O 25.

ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) - THE SINGLE INSTITUTION EXPERIENCE

Plestina S¹, Samarzija M¹

¹Clinical hospital for lung diseases «Jordanovac», Zagreb, Croatia

O 26.

GENE AMPLIFICATION OF EGFR PREDICTS RESPONSE TO GEFITINIB OR ERLOTINIB IN NSCLC: A META-ANALYSIS BASED ON A COMPREHENSIVE EGFR SOMATIC MUTATION DATABASE.

Murray S¹, Linardou H², Dahabreh IJ³, Kosmidis P⁴, Bafileukos D²

¹Department of Molecular Biology & Genetics, Metropolitan Hospital, Athens, Greece, ²First Department of Oncology, Metropolitan Hospital, Athens, Greece, ³Medical School, National University of Athens, Athens, Greece, ⁴Second Department of Oncology, Hygeia Hospital, Athens, Greece

O 27.

OUTCOMES OF SMALL CELL LUNG CANCER PATIENTS TREATED WITH SECOND-LINE CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF 166 PATIENTS

Califano R¹, Blackhall F¹, Michetti G², Lo Dico M³, La Verde N⁴, Aglione S⁵, Gallerani E⁶, Galetta D⁷, Fatigoni S⁸, Torri V⁹, Garassino M⁴

¹The Christie NHS Foundation Trust, Manchester, UK, ²Ospedali Riuniti di Bergamo, Bergamo, Italy, ³Azienda Ospedaliera di Livorno, Livorno, Italy, ⁴Ospedale Fatebenefratelli-Oftalmico, Milano, Italy, ⁵Azienda Ospedaliera di Vimercate, Vimercate (MI), Italy, ⁶Ospedale Cantonale di Bellinzona, Bellinzona, Switzerland, ⁷Istituto dei Tumori, Bari, Italy, ⁸Azienda Ospedaliera di Terni, Terni, Italy, ⁹Istituto Mario Negri, Milano, Italy



O 28.

TOXICITY OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER: DATA FROM CLINICAL PRACTICE

Okutur K.¹, Aydin K.¹, Bozkurt M.¹, Turan C.², Demir N.², Hasbal B.², Erdem L.³, Tecimer C.¹, Demir G.¹

¹Istanbul Bilim University, School of Medicine, Medical Oncology Department, Istanbul, Turkey, ²Istanbul Bilim University, School of Medicine, Internal Medicine Department, Istanbul, Turkey, ³Istanbul Bilim University, School of Medicine, Gastroenterology and Hepatology Department, Istanbul, Turkey

O 29.

CLINICAL FACTORS ASSOCIATED WITH OUTCOME IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH SUNITINIB. AN ANALYSIS BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP

Bamias A.¹, Lampaki S.², Karadimou A.¹, Lainakis G.¹, Maletou L.³, Timotheadou E.², Papazisis K.⁴, Andreadis C.⁴, Kontovinis L.⁴, Anastasiou I.⁵, Stravodimos K.⁵, Xanthakis I.², Skolarikos A.⁵, Christodoulou C.⁶, Syrigos K.⁷, Papandreu C.⁸, Razi E.⁹, Fountzilas G.², Dimopoulos A.¹

¹Department of Clinical Therapeutics, University of Athens, Medical School, Athens, Greece, ²Department of Medical Oncology, «Papageorgiou» Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece,

³Hellenic Cooperative Oncology Group Data Office, Athens, Greece, ⁴Theagenion Cancer Hospital, 3rd Department of Medical Oncology, Thessaloniki, Greece, ⁵Department of Urology, University of Athens, Medical School, Athens, Greece, ⁶Metropolitan Hospital, Athens, Greece, ⁷3rd Department of Internal Medicine, University of Athens, Medical School, Athens, Greece, ⁸Larisa University Hospital, Larisa, Greece, ⁹Hygeia Hospital, Athens, Greece

O 30.

HEPATITIS PREVALENCE IN PANCREATIC ADENOCARCINOMA

Dogan M.¹, Arpacı E.², Dogan L.³, Yalcintas Arslan U.², Ozal G.¹, Urur Y.¹, Bayram M.⁴, Utkan G.¹, Tokluoglu S.², Yalcin B.¹, Demirkazik A.¹, Alkis N.³, Icli F.¹

¹Ankara University, School of Medicine, Department of Medical Oncology, Ankara, Turkey, ²Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey, ³Ankara Oncology Education and Research Hospital, Department of General Surgery, Ankara, Turkey, ⁴Ankara University, School of Medicine, Department of Internal Medicine, Ankara, Turkey

11:00-12:20

Workshop II: "Perspectives in Radiotherapy Techniques for Solid Tumours"

— **Chairpersons:** G. Tsakiris (Greece), K. Georgiadis (Greece)

11.00-11.20

— Novel therapeutic approaches (3D Conformal RT, IMRT)

P. Tsekeris (Greece)

11.20-11.40

— The role of the specialist in radio-physics

N. Marinou (Greece)

11.40-12.00

— The role of the technician-radiologist

M. Michailidis (Greece)

12.00-12.20

— Discussion

Organized by the Technical University of Athens (TEI)

H A L L — — — — —





STARTS STRONG LASTS LONG

Η 2η ΓΕΝΙΑ ΤΩΝ 5-HT3 ΑΝΤΑΓΩΝΙΣΤΩΝ

A male swimmer is performing the butterfly stroke in a swimming pool. He is in mid-stroke, with his head above water and arms extended forward. His body is arched, and he is propelling himself through the water with strong, powerful kicks. The water around him is splashing and creating white foam, particularly around his head and arms. The background shows the blue water of the pool.

ΑΛΛΑΖΕΙ ΤΑ ΔΕΔΟΜΕΝΑ ΜΕ ΜΙΑ ΚΑΙ ΜΟΝΑΔΙΚΗ ΔΟΣΗ

ΕΠΙΧΕΙΡΗΣΗ ΤΟΥ ΑΝΘΡΑΚΙΤΟΥ ΠΛΑΙΟΥΣ: Άλλο 250 μετρόποδαρο επίπεδο θέλιμος. **ΧΩΔΥΓΙΑ ΚΑΙ ΕΠΙΣΤΟΛΗ ΣΥΝΕΙΔΗΣΗΣ:** Ήγε τε διάλυστο περιηγητή 50 μετρόποδαρο πολεοντόρον; Ήγε, ίμε υψηλόβαθμο! Καθώς φιλούσε 5 μετρόποδαρο, περίπου 750 μετρόποδαρο υπόλοιπότερον; Ήγε, ίμε υψηλόβαθμο! **Επικοινωνία, γειτονία:** Τα Λακού εδωπούνται να την πρέπει την, οδούς ναυαρι, και τα ίδια που την πρέπει να είναι απόλυτη υπεροχειώδης καριέρα και που πρέπει της κανταρίας, και που άστρα που σχεδιάζεται με μεταλλικό υπόβαθρον καρκίνου. **Αντανακλάση:** Η προσωποποίηση από δραστική ουσία δεν κάνει από την έδωση. **Βαθειάς προσβολής:** Η πληθωρική προσβολή, μετέ τη δραστική. Καθώς ο προσευχέαρχη μπορεί να πλέονται τα δραστικά στην είσοδο, απογειώνεται με απόριτο δικούσιοτης η πληθωρικής ενέργειας αποκαθίστησης πράττει τη παραμονήδικτη: από την πλευρά της. Τε σαρώνει τη γεράπηγη πολεοντόρη, 750 μετρόποδαρο, έρχεται ορεκτικής. Βαθειάς προσβολής πιττάρης με πιττάρηση καταρράκτη, με τα ποταμούς παραπλήσια λασπονή για απόστρας στην κατούσα. Τα άλλα διαστάσεια σπάνια τα μπαίνουν έξτραθληκά. Η πολεοντόρη δεν προκαλεί

ελκήσεις, σημαντική επιμήκυνση του διαστάσεως GTc. Ωστόσο, ούτε και με τα πλέον διάδοχα αντίγραφα της 5-ΗΤζ, η αρίθμηση των πολλών περιπτώσεων μετατροπής προκύπτει, ότι από τις αιδίσκους της διάστασης GT ή περισσότερες που έγινε ή από την πλειάρχεια των αντιτύπων αποτύπων των διαστάσεων GT. Αναλυτικά αναφέρεται: Σε κλινικές μάλιστας στην περιοχή περιβόλου δομής 250 μικροπράσινων (πλούτος 633 αιδίσκων) ή ότι αποτελείται από περιπτώσεις αντιτύπων αιδίσκων, που είναι δυνατό τον άριθμό των περιπτώσεων με το Άτον, γιατί καθολικά το 95% είναι διακοπέμενα [11]. Τις κλινικές μάλιστας περιπτώσεων που αποτελούνται από περιπτώσεις ενεργειών (AE) ή αιτησης, είναι δυνατόν ν' ιδούνται στην περιοχή της Ατόνης. Αυτές τοποθετήσεων ως συρροής μεταβολή 1% κατά 10%. Καρότσα, θέση, διακοπέμενη, βαρόση ή στη συρροή μεταβολή 0,1% κατά 1%. Υπερεξάστη, δερματοπολιτικής, αιτησηών, υποστομίας, περιοδοντικής, πικραλού, πικραλών φύσεων, περιφέρεια, ιστηλά, αιτησηών, περιπτώσεων, περιπτώσεων αιτησηών περιπτώσεων, αφρικάσιας, προστάσεων, αιδίσκων, ύδρος των πελμάτων, πλευρικής, πανεπιδημία, δραματικού, εκπτώσης, μετατόπισης,

τος μικρόβιου, φλεγμονώδη ταυχέριδη, φλεγμονώδη αρρώσια, μεταρρυθμίσεις (πάκτωση, επιστρέψη, κλινωση, πτωτισμός), μετεξύ θεραπειών, δεύτερης γένους. Ικόνεςς: διατήρηση, κακώς άγριος ή αισιοδοξός σίνετος, έπρωτη ουρή, υπερδιάλυψη, αύξηση πορείας έξαρσης, νοσος αναβοστή με χαστούκια, αύξηση όποιου προστατευτικού μεταβολισμού. Μετατρέπεται σε θεραπεία QT από ΗΚΤ. Αναφέρεται πολλόποιο (>10.000) παρατητικό απόρροια υπερδιάλυψης, καθώς απόρροια με παρατητική ισχύ, ικόνεςς, αύξησης, πτωτισμού και πορείας απαλλαγής από την καλύπτοσθη την πρώτη φορά. Στη συνέχεια η ικόνη της ΑΓΓΕΛΙΑΣ ΕΠΙΧΕΙΡΗΣΗΣ θα γίνεται η Φαρμακοτεραπεία Λαζαρίδη Μητέλια Διάτη Βαρύτερης Αγγελιακής Κυανοκρότησης (πάνω από 2000 μεταβολικές ικόνες). Αριθμός Αγγελιακής Κυανοκρότησης: 110-111-1111-1111. Ημερομηνία Απόστασης: Μάρτιος 2008.

Για πάρετε συντελευτική; Η πληροφορία προσέρχεται από την επικοινωνία μεταξύ της Επιτροπής Εθνικής Στρατηγικής Ανάπτυξης και της Κυβερνητικής Επιτροπής Ανάπτυξης.

BIBLIOPATRIA: Wong EH et al. Br J Pharmacol 1995; 114: 891-9. Atmel Summary of Product Characteristics 2005. Gralna R et al. Ann Oncol 2003; 14: 1570-1577. Eisenberg P et al. Cancer 2003; 98: 2473-2482. Hesketh P. Scop. Care Cancer 2004; 12:550-4.


 Galenica

Αδρήνα: Ελευθερίας 4, Κηφισιά 145 64, τηλ.: 210 5281700
Θεσσαλονίκη: Κουντουριώτου & Φασιάνου 2, τηλ.: 2310 542685

HELSINN

TEVAGRASTIM®

TG/03.2009



Κάτοχος Άδειας Κυκλοφορίας: Teva Generics GmbH, Kandelstr. 10, DE-79199 Kirchzarten, Γερμανία.

Σύνθεση: Κάθε ml ενέσιμου διαλύματος ή διαλύματος για έγχυση διεθνείς μονάδες [MIU] (600 µg) φιλγραστίμης. **Tevagratim 30 MIU/0,5 ml ενέσιμο διάλυμα ή διάλυμα για έγχυση:** Κάθε προγειωμένη σύριγγα περιέχει 30 MIU (300 µg) φιλγραστίμης σε 0,5 ml ενέσιμου διαλύματος ή διαλύματος για έγχυση. **Tevagratim 48 MIU/0,8 ml ενέσιμο διάλυμα για έγχυση:** Κάθε προγειωμένη σύριγγα περιέχει 48 MIU (480 µg) φιλγραστίμης σε 0,8 ml ενέσιμου διαλύματος ή διαλύματος για έγχυση. Η φιλγραστίμη (ανθρώπινος παράγοντας διέγερσης αποικιών των κοκκιοκυττάρων ανασυνδυασμένου μεθιονυλίου) παράγεται σε Escherichia coli K802 από τεχνολογία ανασυνδυασμένου DNA.

Τρόπος Διάθεσης: Μόνο για Νοσοκομειακή χρήση και μόνο από ειδικά Ογκολογικά και Αιματολογικά Κέντρα που έχουν πείρα στη χρήση του r-metHuG-CSF και τις απαραίτητες διαγνωστικές δυνατότητες. Οι διαδικασίες κινητοποίησης και λευκαφαίρεσης θα πρέπει να πραγματοποιούνται σε συνεργασία με ένα ογκολογικό - αιματολογικό κέντρο που έχει ικανοποιητική εμπειρία σε αυτόν τον τομέα και όπου ο έλεγχος των αιμοποιητικών προγονικών κυττάρων μπορεί να γίνει σωστά

Περαιτέρω πληροφορίες διατίθενται από την



TEVA Pharmaceuticals Hellas S.A.

Κηφισίας 166Α Σοφοκλέους 2, 151 26 Μαρούσι, Ελλάδα
Τηλ: +30210 7279099, www.tevaeurope.com

scientific information

Venue and dates



The Congress will take place in Athens, in **September 10-13, 2009** at the **Astir Palace Resort; Vouliagmeni - The Westin Athens building**, 40 Apollonos str., Vouliagmeni - Athens.

Tel: +30 210 8902000, Fax: +30 210 8962582, website: www.astir-palace.com

Forum Website

The Congress website is: www.MediterraneanOncologyForum2009athens.gr

Language

The official language of the Congress is English.

Continuing Medical Education

The 1st Congress of the Mediterranean Multidisciplinary Oncology Forum has been accredited by the European Society for Medical Oncology (ESMO) with **24 ESMO-MORA points**, category I.

Certificate of Attendance

A certificate of attendance will be given to each registered participant, on September 12, 2009.

Awards

Three Awards will be given for the best Presentations. Winners will be chosen on the basis of the scientific merit of their work and the quality of their presentation. The Awards will be given during the Closing Ceremony, on Saturday, 12 September 2009, at 20.00 hrs.

The Best Clinical Research Work is granted by Roche Hellas

The Best Translational Research Work is granted by Merck Hellas

The Best Poster Presentation Work is granted by Novartis Hellas

Proffered Papers

All authors have been informed in writing of details concerning the exact time, day and duration of their presentation. Sessions of Proffered Papers are held on September 10 and 12 at Hall I & II. All Congress Halls are equipped with data video projectors for Power Point presentations, laser pointers etc.

Poster Presentations

Posters have been numbered and listed according to the Scientific Committee's instructions.

Posters will be affixed at the Poster Area – Hall III.

All Posters should be mounted, on **Thursday, September 10, 2009**, between **09.00- 10.00 hours** and dismounted on **Saturday, September 12, 2009** after **20.30 hrs**.

Posters Size: Maximum width: 70 cm, Maximum Height 120 cm. Only scotch tape and selfadhesive pads are allowed

PC Reception

A preview room with a slide reception desk for acceptance and checking of slides, or a CD or on a "disk on Key" (external memory stick), will be located near the Congress Halls. All slides and PC disks should be clearly labelled with the author's name and the respective session. Slides must be 50 x 50 mm in plastic mounts and should bear an indication of the correct direction of insertion. Speakers are kindly requested to provide their slides or their PC disks at least one hour prior to their respective presentation.



Exhibition

A commercial exhibition of pharmaceutical items and technical equipment will take place in Exhibition Hall during the Congress hours.

Internet corner

Computer workstations with access to the Internet will be provided free of charge for all participants, during exhibition hours.

Smoking policy

Smoking is prohibited at all times in the congress halls, exhibit halls and restrooms. Your compliance is appreciated.

Mobile phones

Please note that mobile phones must be switched off during all sessions.

Insurance

The 1st Mediterranean Multidisciplinary Oncology Forum accepts no liability for any personal injury, loss or damage of property belonging or additional expenses incurred to Congress participants either during the Congress or as result of delays, strikes or any other circumstances. Participants are requested to make their own arrangements with respect to health and travel insurance.

Shopping in Athens

In Athens the usual opening hours for shops are:

- Monday, Wednesday & Saturday from 09.30-14.30 hours
- Tuesday, Thursday & Friday from 09.30-14.30 hours and from 17.30-20.30 hours

These times are not always strictly adhered to. Many shops in tourist resorts are open seven days a week. Departments' stores and supermarkets are open from 09.00-20.00 hours (Monday- Friday) and from 08.00-15.00 hrs (Saturday) and are closed on Sunday. Post offices are open from 07.30-14:00 hours (Monday-Friday). Tourist shops in Plaka stay open on Sunday also.

Weather

Typically mediterranean climate. Athens enjoys relatively mild winters and lovely, temperate autumns and springs. The climate is pleasant, and sunshine is plentiful. September is warm without being stifling, the swimming is excellent and the temperature ranges from 25°C to 35°C.

Transportation

Athens Airport

The Athens International Airport is located in Spata, 27 Kms north-east of Athens and handles all international and domestic flights. For more information please visit the Eleftherios Venizelos website: <http://www.aia.gr>. A special feature of this web site is that on the home page you can link to live arrival and departure information by clicking on the link Real Time Flight Information.

The Athens International Airport "Eleftherios Venizelos" is linked to the Athens city center by:

• From Airport by Bus:

Three express lines serve the Athens International Airport to Athens City Center on a 24 hours basis. The bus line E9 5 (Direction Syntagma) serves Athens City center (Syntagma, Constitution Square). The following timetable is applicable:

From Airport to Syntagma area	From Syntagma area to Airport
Every 25' from 06.30 to 21.20	Every 25' from 06.00 to 20.40
Every 25'-35' from 21.20 to 06.30	Every 25'-35' from 20.40 to 06.00

Current ticket price for the airport express line is 3,20 euro

• From Airport by Taxi: An average journey by taxi from Eleftherios Venizelos Airport to City Centre should take approximately 30- 45 minutes, depending on the traffic. The cost of the ride should be around 25-28 per way.

Kindly note, there is a temporary suspension of operation of Athens Metro in the station of the airport, in order to complete the necessary construction works for new lines.



general information

Registration fees

Type of Registration	Until July 20 th , 2009	After July 20 th , 2009
ESMO MEMBERS	€ 250	€ 300
NON-ESMO MEMBERS	€ 350	€ 400
DENTISTS	€ 250	€ 300
JUNIOR ONCOLOGISTS-NURSES-TECHNICIANS	€ 100	€ 100

The registration fees for the ESMO Members, Non ESMO Members, Dentists include: Access to the Scientific Sessions and Exhibition, Welcome Reception, Gala Dinner, Coffee Breaks, Light Lunches, Congress Material (Congress kit, Final Programme & Book of Abstracts, Certificate of Attendance)

The registration fees for the Junior Oncologists, Nurses and Technicians include: Access to the Scientific Sessions and Exhibition, Welcome Reception, Coffee Breaks, Light Lunches, Congress Material (Congress kit, Final Programme & Book of Abstracts, Certificate of Attendance)

Accommodation package

FOR ALL PARTICIPANTS:

€ 870

Accommodation Package for participants includes: Single room for three (3) overnights (**10-13 September 2009**) breakfast and taxes included as well as Airport Transfers (Arrival & Departure)

FOR ACCOMPANYING PERSONS:

€ 360

Accommodation Package for accompanying persons includes: Double room sharing with participant for three (3) nights (**10-13 September 2009**) breakfast and taxes included, Welcome Reception, Gala Dinner as well as Airport Transfers (Arrival & Departure)

Hotel Accommodation before & after the Course Period - (Daily Hotel room rates including breakfast and taxes)

HOTEL	Single Room	Double Room
The Westin Astir Palace	265 €	285 €
The Margi	180 €	200 €
Plaza Vouliagmeni	125 €	135 €

Social Activities

- Opening Ceremony and Welcome Reception.** The Opening Ceremony of the 1st Congress of the Mediterranean Multidisciplinary Oncology Forum will take place on **Thursday, September 10, 2009 20.00**. Welcome Reception will follow at the veranda of the Acropolis Museum Restaurant, for all participants and registered accompanying persons.
- Gala Dinner.** The Gala Dinner 1st Congress of the Mediterranean Multidisciplinary Oncology Forum will take place on **Saturday, September 12, 2009 at 21.00 at the "Grill Room Terrace Restaurant" of the Astir Palace Resort**, for all participants and registered accompanying persons

Daily optional tours during congress

A. Athens Sightseeing Tour (morning tour) – 09.00-12.30 hrs – Daily service

A view to the city's everlasting thrills. The University, Academy, House of Parliament, Temple of Olympian Zeus, Presidential Residence and Panathenian Stadium – the place where the first Olympics of Modern Times were held. But mastering all, is the visit to imposing Acropolis and its Museum.

Cost per person: € 50

B. Cape Sounion (afternoon tour) – 15.00-19.00 hrs – Daily service

Distance from Athens City: 70 km The spectacular coastal drive past the beaches of Glyfada, Vouliagmeni and Varkiza, will take you to Cape Sounion, which is dominated by the Temple of Poseidon.

Cost per person: € 38



C. Delphi – Full day tour – 08.45-19.00 hrs – Daily service

Travel distance: 190 km (3 hours drive) from Athens. Drive through the spectacular sites of Beotia, Thebes, Levadia and arriving in Arachova, known for its colourful rugs and carpets. Proceed to Delphi, once referred to as the Center of Earth. You will visit the Temple of Apollo and its Museum, exhibiting amongst other masterpieces, the ancient Greek sculpture of the Bronze Charioteer. Lunch will be served at a traditional taverna in Delphi. Early evening return to Athens.

Cost per person: € 93 including lunch (beverage consumption is not included)



D. Argolis – Full day tour – 08.45-19.00 hrs – Except Sundays, Mondays & Fridays

Travel distance 380 km from and to Athens. Leave by the coastal road along the Saronic Gulf to the Corinth Canal. Drive on to Mycenae, the Homeric city of Atreides. Visit the Lion's Gate, the Cyclopean Walls, the Royal Tombs. Depart for Nafplion through Argolis, the picturesque town nestling at the foot of a cliff crowned by the mighty ramparts of the Palamidi Fortress and leave to Epidaurus. Lunch will be served at Mycenae or Nafplion. Early evening return to Athens.

Cost per person: € 93 including lunch (beverage consumption is not included)



E. One-Day cruise to Saronic Islands (Aegina, Poros & Hydra) - 08.00-19.15 hrs – Daily service

Morning transfer to the port of Piraeus to embark your cruise ship. Sail to the island of Aegina and a chance to visit the famed Temple of Afea Athena (optional). Embarkation and sail for Poros. Enjoy a beautiful walk up to the clock tower and admire the panorama. Lunch will be served during the voyage to Hydra. Hydra is one of the most beautiful islands of the Saronic Gulf with unique architecture and narrow streets full of boutiques, jewellery and handicrafts. Evening arrival to Piraeus and transfer to your hotel.

Cost per person: € 93 including lunch (Beverage consumption is not included)



Notes: All tours (A, B, C & D) will be performed by air-conditioned motor coaches, with English speaking guides including entrance fees to the museums and archaeological sites visited. Pick up and Drop off service from the city centre and coast Hotels. The exact pick up time will be mentioned on the Tour ticket.



Cancellation of registration

Cancellation requests must be made to the Congress Secretariat in writing. For cancellation received by **July 20th, 2009**, a refund of the total fee, less 30% as administration charge, will be made. After that date refunds will not be possible.



Payment conditions for accommodation package and tours

- **50% deposit**, payable to ERA Ltd, is required in order to confirm the Accommodation Package and Tours
- **Full payment** for Accommodation package and Tours should reach the Congress Secretariat not later than **July 30th, 2009**

Cancellation policy for Accommodation Package & tours

- For written cancellation by **June 20th, 2009**: No Cancellation fees.
- Written cancellation received till **July 20th, 2009**: 50% Cancellation fees apply.
- Written cancellation received after **July 20th, 2009**: 100% cancellation fees apply.

Congress Secretariat & Official Travel Agency

For any information regarding Abstract Submission, Registration, Accommodation, Travel or Exhibition please contact the Congress Secretariat & official Travel agency:



ERA Ltd 17 Asklipiou Str., 106 80, Athens, Greece
Tel: +30 210 3634944, Fax: +30 210 3631690, e-mail: info@era.gr
website: www.era.gr



Oxaliplatin/TEVA

5 mg/ml

1 ml πυκνού
διαλύματος
για έγχυση περιεχει
5 mg Oxaliplatin

NEO
προϊόν

- Oxaliplatin/TEVA
50 mg/10 ml



- Oxaliplatin/TEVA
100 mg/20 ml

Περαιτέρω πληροφορίες διατίθενται από την

TEVA

TEVA Pharmaceuticals Hellas S.A

Κηφισίας 166A Σοφοκλεους 2, 151 26 Μαρούσι, Ελλάδα
Τηλ: +30210 72 79 099, www.tevapharm.com

The Organizing Committee of the
1st Congress of the
Mediterranean Multidisciplinary Oncology Forum
gratefully acknowledges the contribution to the organization of the Congress
of the following:

PLATINUM SPONSOR



We Innovate Healthcare

SILVER SPONSOR



BRONZE SPONSOR



Also, the Organizing Committee appreciates the Support and the Participation of the following Companies (in alphabetical order):



TEVA Pharmaceuticals Hellas S.A.



exhibition plan

1st CONGRESS OF THE MEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM,
10-13 SEPTEMBER 2009, ASTIR PALACE, ATHENS-GREECE



Name of Company	No of Stand
PHARMASERV LILLY	No 1
VIANEX SA	No 2
BAYER HEALTHCARE	No 5
WYETH	No 6
PIERRE FABRE	No 7
MERCK SERONO	No 9
GALENICA SA	No 10

Name of Company	No of Stand
ROCHE HELLAS	No 11
GLAXO SMITHKLINE	No 12+19
GENESIS PHARMA	No 13
SANOFI AVENTIS	No 14
NOVARTIS HELLAS SA	No 15
ASTRA ZENECA	No 16

GONGRESS PROCEEDINGS

DISCLAIMER

Every effort has been made to correct the texts submitted for any grammatical and syntax oversights.

However, the shortage of time and the pressure to have this book available at the Congress prohibited an extensive editorial work. Therefore, some texts may contain grammatical, syntax or typographical errors. The editorial group pleads to reader's understanding for such oversights. The views presented in the following texts are those of the respective authors. The Editorial group, the Organizing Committee and the Publisher do not accept any responsibility for the views presented; these are the sole responsibility of the respective authors. Dosage of medications reported should not be taken as an authoritative reference; it is recommended that any dosage presented in the book verified with the authors.

40,000

EPREX
epoetinum alfa



JANSSEN-CILAG

56, Eirinis Avenue, 15121, Pefki-Athens, Tel.: 210-6140061
8,3 km Thessalonikis - Moudanion Avenue, Pilaia, Thessaloniki,
Tel.: 2310-470800, www.janssen-cilag.gr